RecentMedicalFindings.com
Summarizing relevant biomedical research!
clostridium difficile     Bookmark and Share
Search webpages of this site (RecentMedicalFindings):
Didn't find what you wanted? Try it at BioMedLib™ !
Search directly on the biomedical articles using BioMedLib™ search engine:



1. Biomedical articles (top 50; 2009 to 2014)
1. |||||||||. 100%  Lee NY, Huang YT, Hsueh PR, Ko WC: Clostridium difficile bacteremia, Taiwan. Emerg Infect Dis; 2010 Aug;16(8):1204-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium difficile bacteremia, Taiwan.
  • To determine clinical characteristics and outcome of patients with Clostridium difficile bacteremia (CDB), we identified 12 patients with CDB in 2 medical centers in Taiwan; all had underlying systemic diseases.
  • Five isolates had C. difficile toxin A or B.
  • Of 8 patients treated with metronidazole or vancomycin, only 1 died, and all 4 patients treated with other drugs died (12.5% vs. 100%; p = 0.01). C. difficile bacteremia, although uncommon, is thus associated with substaintial illness and death rates.
  • [MeSH-major] Anti-Bacterial Agents / pharmacology. Bacteremia / microbiology. Clostridium difficile / isolation & purification. Enterocolitis, Pseudomembranous / microbiology

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Clostridium Difficile Infections.
  • HSDB. structure - VANCOMYCIN.
  • HSDB. structure - METRONIDAZOLE.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Microbiol Infect. 2001 Aug;7(8):453-7 [11591212.001]
  • [Cites] Anaerobe. 2009 Dec;15(6):249-51 [19723585.001]
  • [Cites] J Clin Microbiol. 2003 Jun;41(6):2454-7 [12791864.001]
  • [Cites] Am J Med. 2003 Jun 15;114(9):770-1 [12829209.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):230-7 [12856216.001]
  • [Cites] Am J Surg. 1982 Apr;143(4):519-22 [6280507.001]
  • [Cites] J Infect Dis. 1983 Jun;147(6):1105 [6854068.001]
  • [Cites] Arch Pathol Lab Med. 1984 Jan;108(1):82-3 [6546347.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Sep 1;289(6444):531-2 [6432176.001]
  • [Cites] J Clin Pathol. 1985 Apr;38(4):445-51 [3857233.001]
  • [Cites] Crit Care Med. 1985 Oct;13(10):818-29 [3928249.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Am J Gastroenterol. 1987 Apr;82(4):389-90 [3565349.001]
  • [Cites] Am J Infect Control. 1988 Jun;16(3):128-40 [2841893.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1989 Apr;8(4):300-2 [2497002.001]
  • [Cites] Chest. 1992 Jun;101(6):1644-55 [1303622.001]
  • [Cites] Medicine (Baltimore). 2001 Mar;80(2):88-101 [11307591.001]
  • [Cites] Clin Infect Dis. 2001 Aug 1;33(3):349-53 [11438901.001]
  • [Cites] J Microbiol Immunol Infect. 2001 Jun;34(2):113-8 [11456356.001]
  • [Cites] JAMA. 1993 Dec 22-29;270(24):2957-63 [8254858.001]
  • [Cites] N Engl J Med. 1994 Jan 27;330(4):257-62 [8043060.001]
  • [Cites] Clin Infect Dis. 1995 Jun;20(6):1560-2 [7548512.001]
  • [Cites] Clin Infect Dis. 1996 Apr;22(4):712 [8729213.001]
  • [Cites] J Clin Microbiol. 1998 Apr;36(4):1167-8 [9542965.001]
  • [Cites] Clin Infect Dis. 1998 Jun;26(6):1413-7 [9636872.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):943-7 [9787741.001]
  • [Cites] J Bacteriol. 1962 Jul;84:65-7 [13914327.001]
  • [Cites] Lancet Infect Dis. 2005 Sep;5(9):549-57 [16122678.001]
  • [Cites] Clin Microbiol Infect. 2006 Oct;12(10):1006-12 [16961638.001]
  • [Cites] Ann Intern Med. 2006 Nov 21;145(10):758-64 [17116920.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Apr;22(4):464-71 [17376034.001]
  • [Cites] Clin Microbiol Infect. 2008 Nov;14(11):1057-64 [19040478.001]
  • [Cites] Nat Rev Microbiol. 2009 Jul;7(7):526-36 [19528959.001]
  • [Cites] Int J Infect Dis. 2009 Sep;13(5):e305-9 [19398213.001]
  • [Cites] J Clin Microbiol. 2002 Jan;40(1):101-4 [11773100.001]
  • (PMID = 20678312.001).
  • [ISSN] 1080-6059
  • [Journal-full-title] Emerging infectious diseases
  • [ISO-abbreviation] Emerging Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 140QMO216E / Metronidazole; 6Q205EH1VU / Vancomycin
  • [Other-IDs] NLM/ PMC3298294
  •  go-up   go-down


2. |||||||||. 99%  Southern WN, Rahmani R, Aroniadis O, Khorshidi I, Thanjan A, Ibrahim C, Brandt LJ: Postoperative Clostridium difficile-associated diarrhea. Surgery; 2010 Jul;148(1):24-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative Clostridium difficile-associated diarrhea.
  • BACKGROUND: Abdominal surgery is thought to be a risk factor for Clostridium difficile-associated diarrhea (CDAD).
  • [MeSH-major] Clostridium difficile / pathogenicity. Diarrhea / etiology. Enterocolitis, Pseudomembranous / etiology. Postoperative Complications / etiology

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • Genetic Alliance. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Clostridium Difficile Infections.
  • MedlinePlus Health Information. consumer health - Diarrhea.
  • COS Scholar Universe. author profiles.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • [Cites] Stat Med. 1998 Oct 15;17(19):2265-81 [9802183.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):296-301 [9488530.001]
  • [Cites] Clin Transplant. 1999 Aug;13(4):318-23 [10485373.001]
  • [Cites] Arch Surg. 2005 Aug;140(8):752-6 [16103284.001]
  • [Cites] CMAJ. 2005 Oct 25;173(9):1037-42 [16179431.001]
  • [Cites] JAMA. 2005 Dec 21;294(23):2989-95 [16414946.001]
  • [Cites] CMAJ. 2006 Sep 26;175(7):745-8 [17001054.001]
  • [Cites] J Hosp Infect. 2007 Jan;65(1):42-6 [17145108.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):314-6 [17227985.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Mar;5(3):345-51 [17368234.001]
  • [Cites] Ann Thorac Surg. 2007 Apr;83(4):1396-402 [17383346.001]
  • [Cites] BMC Infect Dis. 2007;7:42 [17517130.001]
  • [Cites] Arch Surg. 2007 Jul;142(7):624-31; discussion 631 [17638799.001]
  • [Cites] J Antimicrob Chemother. 2001 Jan;47(1):43-50 [11152430.001]
  • [Cites] Lancet. 2001 Jan 20;357(9251):189-93 [11213096.001]
  • [Cites] J Hosp Infect. 2001 Jun;48(2):93-7 [11428874.001]
  • [Cites] Can J Surg. 2002 Jun;45(3):173-80 [12067168.001]
  • [Cites] Infect Control Hosp Epidemiol. 2002 Nov;23(11):653-9 [12452292.001]
  • [Cites] J Clin Microbiol. 2003 Sep;41(9):4031-7 [12958221.001]
  • [Cites] Clin Ther. 2004 Feb;26(2):197-213 [15038943.001]
  • [Cites] J Infect Dis. 2004 May 1;189(9):1585-9 [15116293.001]
  • [Cites] Ann Surg. 1977 Sep;186(3):251-9 [889372.001]
  • [Cites] Emerg Infect Dis. 2007 Sep;13(9):1417-9 [18252127.001]
  • [Cites] Emerg Infect Dis. 2008 Jun;14(6):929-31 [18507904.001]
  • [Cites] Emerg Infect Dis. 2008 Jul;14(7):1031-8 [18598621.001]
  • [Cites] J Gastrointest Surg. 2008 Sep;12(9):1512-7 [18612709.001]
  • [Cites] Am J Gastroenterol. 2008 Sep;103(9):2308-13 [18702653.001]
  • [Cites] J Infect Dis. 1985 Mar;151(3):476-81 [3973405.001]
  • [Cites] Drugs Exp Clin Res. 1985;11(3):201-5 [3915287.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Ann Intern Med. 1989 Feb 15;110(4):255-7 [2643913.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] Arch Intern Med. 1992 Aug;152(8):1715-7 [1497405.001]
  • [Cites] Eur Surg Res. 1992;24(3):133-7 [1499601.001]
  • [Cites] Am Surg. 1994 Mar;60(3):169-74 [8116975.001]
  • [Cites] Arch Surg. 1996 Dec;131(12):1333-7 [8956776.001]
  • [Cites] Eur J Vasc Endovasc Surg. 1997 Sep;14(3):217-20 [9345243.001]
  • [Cites] Clin Infect Dis. 1998 Jan;26(1):141-5 [9455523.001]
  • [Cites] Ann Intern Med. 1998 Dec 15;129(12):1012-9 [9867755.001]
  • (PMID = 20116817.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI051519-01A1; United States / NIAID NIH HHS / AI / P30 AI51519
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS162865; NLM/ PMC2886164
  •  go-up   go-down


3. |||||||||. 92%  Naaber P, Stsepetova J, Smidt I, Rätsep M, Kõljalg S, Lõivukene K, Jaanimäe L, Löhr IH, Natås OB, Truusalu K, Sepp E: Quantification of Clostridium difficile in antibiotic-associated-diarrhea patients. J Clin Microbiol; 2011 Oct;49(10):3656-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of Clostridium difficile in antibiotic-associated-diarrhea patients.
  • Comparing culture- and non-culture-based methods for quantifying Clostridium difficile in antibiotic-associated-diarrhea patients, we found that the real-time PCR method correlated well with quantitative culture and was more sensitive.
  • A positive association between the population levels of C. difficile and the presence of its toxins was found.
  • [MeSH-major] Anti-Bacterial Agents / adverse effects. Bacterial Load / methods. Clostridium Infections / microbiology. Clostridium difficile / isolation & purification. Diarrhea / microbiology

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • Genetic Alliance. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Diarrhea.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hosp Infect. 2009 Jan;71(1):43-8 [19041162.001]
  • [Cites] Indian J Med Res. 2008 May;127(5):472-7 [18653911.001]
  • [Cites] Dis Mon. 2009 Jul;55(7):439-70 [19540996.001]
  • [Cites] Clin Microbiol Infect. 2009 Dec;15(12):1053-66 [19929972.001]
  • [Cites] J Clin Microbiol. 1992 May;30(5):1238-42 [1583125.001]
  • [Cites] J Clin Microbiol. 1994 May;32(5):1360-1 [8051268.001]
  • [Cites] J Clin Microbiol. 1995 Jul;33(7):1755-9 [7665642.001]
  • [Cites] Clin Diagn Lab Immunol. 1997 Nov;4(6):719-22 [9384296.001]
  • [Cites] J Appl Microbiol. 2004;97(6):1166-77 [15546407.001]
  • [Cites] Microbiol Immunol. 2004;48(11):889-92 [15557747.001]
  • [Cites] FEMS Microbiol Lett. 2005 Feb 1;243(1):141-7 [15668012.001]
  • [Cites] Lancet Infect Dis. 2005 Sep;5(9):549-57 [16122678.001]
  • [Cites] FEMS Microbiol Ecol. 2006 Jan;55(1):28-37 [16420612.001]
  • [Cites] J Clin Microbiol. 2006 Feb;44(2):353-8 [16455883.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):779-86 [16804543.001]
  • [Cites] Pediatrics. 2006 Aug;118(2):511-21 [16882802.001]
  • [Cites] Int J Antimicrob Agents. 2009 Mar;33 Suppl 1:S37-41 [19303568.001]
  • (PMID = 21865427.001).
  • [ISSN] 1098-660X
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bacterial Toxins
  • [Other-IDs] NLM/ PMC3187345
  •  go-up   go-down


Advertisement
4. |||||||||. 90%  Gersch M, Sieber SA: Disarming Clostridium difficile. Chem Biol; 2010 Nov 24;17(11):1165-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disarming Clostridium difficile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [CommentOn] Chem Biol. 2010 Nov 24;17(11):1201-11 [21095570.001]
  • (PMID = 21095563.001).
  • [ISSN] 1879-1301
  • [Journal-full-title] Chemistry & biology
  • [ISO-abbreviation] Chem. Biol.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. |||||||||. 89%  Heinlen L, Ballard JD: Clostridium difficile infection. Am J Med Sci; 2010 Sep;340(3):247-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium difficile infection.
  • Clostridium difficile is the leading cause of hospital-acquired diarrhea in Europe and North America and is a serious reemerging pathogen.
  • Recent outbreaks have led to increasing morbidity and mortality and have been associated with a new strain (BI/NAP1/027) of C difficile that produces more toxin than historic strains.
  • With the increasing incidence of C difficile infection, clinicians have also seen a change in the epidemiology with increased infections in previously low-risk populations.
  • This chapter highlights the current knowledge on C difficile virulence, human disease, epidemic outbreaks and optimal treatment strategies.
  • [MeSH-major] Clostridium Infections / epidemiology. Clostridium difficile / isolation & purification

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 1989 Feb;159(2):340-3 [2915158.001]
  • [Cites] JAMA. 1993 Jan 6;269(1):71-5 [8416409.001]
  • [Cites] N Engl J Med. 1994 Jan 27;330(4):257-62 [8043060.001]
  • [Cites] Ann Intern Med. 1994 Feb 15;120(4):272-7 [8080497.001]
  • [Cites] Infect Immun. 1994 Feb;62(2):384-9 [8300199.001]
  • [Cites] J Biol Chem. 1994 Apr 8;269(14):10706-12 [8144660.001]
  • [Cites] Infect Control Hosp Epidemiol. 1994 Feb;15(2):88-94 [8201240.001]
  • [Cites] JAMA. 1994 Jun 22-29;271(24):1913-8 [8201735.001]
  • [Cites] Clin Infect Dis. 1994 May;18 Suppl 4:S265-72 [8086574.001]
  • [Cites] J Clin Invest. 1995 May;95(5):2004-11 [7738167.001]
  • [Cites] Nature. 1995 Jun 8;375(6531):500-3 [7777059.001]
  • [Cites] Infect Control Hosp Epidemiol. 1995 Aug;16(8):459-77 [7594392.001]
  • [Cites] Clin Infect Dis. 1995 Jun;20 Suppl 2:S263-5 [7548570.001]
  • [Cites] Am J Med. 1996 Jan;100(1):32-40 [8579084.001]
  • [Cites] Clin Infect Dis. 1997 Mar;24(3):324-33 [9114180.001]
  • [Cites] J Infect Dis. 1997 Nov;176(5):1233-8 [9359723.001]
  • [Cites] Clin Infect Dis. 1998 Jan;26(1):141-5 [9455523.001]
  • [Cites] Annu Rev Med. 1998;49:375-90 [9509270.001]
  • [Cites] Am J Med. 1998 Jul;105(1):71-2 [9688023.001]
  • [Cites] Infect Control Hosp Epidemiol. 2005 Mar;26(3):273-80 [15796280.001]
  • [Cites] Clin Microbiol Rev. 2005 Apr;18(2):247-63 [15831824.001]
  • [Cites] Clin Infect Dis. 2005 Jun 1;40(11):1586-90 [15889354.001]
  • [Cites] Clin Infect Dis. 2005 Jun 1;40(11):1591-7 [15889355.001]
  • [Cites] JAMA. 2006 Jun 14;295(22):2599-600; author reply 2600-1 [16772617.001]
  • [Cites] Clin Infect Dis. 2006 Aug 15;43(4):411-20 [16838228.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14176-81 [16966605.001]
  • [Cites] CMAJ. 2006 Sep 26;175(7):745-8 [17001054.001]
  • [Cites] Clin Infect Dis. 2007 Aug 1;45(3):302-7 [17599306.001]
  • [Cites] J Med Microbiol. 2005 Sep;54(Pt 9):905-6 [16091446.001]
  • [Cites] Lancet. 2005 Sep 24-30;366(9491):1079-84 [16182895.001]
  • [Cites] CMAJ. 2005 Oct 25;173(9):1037-42 [16179431.001]
  • [Cites] Clin Infect Dis. 2009 Mar 1;48(5):598-605 [19191646.001]
  • [Cites] Int J Surg. 2009 Feb;7(1):78-81 [19070558.001]
  • [Cites] Int J Antimicrob Agents. 2009 Mar;33 Suppl 1:S46-50 [19303570.001]
  • [Cites] Antimicrob Agents Chemother. 2009 May;53(5):2202-4 [19223641.001]
  • [Cites] Nature. 2009 Apr 30;458(7242):1176-9 [19252482.001]
  • [Cites] Arch Surg. 2009 May;144(5):433-9; discussion 439-40 [19451485.001]
  • [Cites] Gastroenterology. 2009 May;136(6):1899-912 [19457418.001]
  • [Cites] Gastroenterology. 2009 May;136(6):1913-24 [19457419.001]
  • [Cites] Nat Rev Microbiol. 2009 Jul;7(7):526-36 [19528959.001]
  • [Cites] Clin Infect Dis. 2009 Feb 15;48(4):e41-6 [19133801.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Aug;7(8):868-873.e2 [19465153.001]
  • [Cites] PLoS Pathog. 2009 Oct;5(10):e1000626 [19834554.001]
  • [Cites] Anaerobe. 2009 Dec;15(6):290-1 [19698797.001]
  • [Cites] Anaerobe. 2009 Dec;15(6):281-4 [19699309.001]
  • [Cites] Anaerobe. 2009 Dec;15(6):285-9 [19778623.001]
  • [Cites] Anaerobe. 2009 Dec;15(6):274-80 [19825425.001]
  • [Cites] Anaerobe. 2009 Dec;15(6):270-3 [19853666.001]
  • [Cites] Diagn Microbiol Infect Dis. 2010 Jan;66(1):24-8 [19775847.001]
  • [Cites] Curr Opin Gastroenterol. 2010 Jan;26(1):17-25 [19881343.001]
  • [Cites] Clin Infect Dis. 2010 Jan 15;50(2):194-201 [20025526.001]
  • [Cites] N Engl J Med. 2010 Jan 21;362(3):197-205 [20089970.001]
  • [Cites] Ann Pharmacother. 2010 Feb;44(2):352-9 [20071495.001]
  • [Cites] Am J Gastroenterol. 2010 Jul;105(7):1636-41 [20145608.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2005 Dec 2;54(47):1201-5 [16319813.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2433-41 [16322603.001]
  • [Cites] JAMA. 2005 Dec 21;294(23):2989-95 [16414946.001]
  • [Cites] Emerg Infect Dis. 2006 Mar;12(3):409-15 [16704777.001]
  • [Cites] Curr Opin Crit Care. 2007 Aug;13(4):450-5 [17599017.001]
  • [Cites] J Gastroenterol. 2007 Jun;42(6):507-8 [17671768.001]
  • [Cites] Ann Clin Lab Sci. 2007 Summer;37(3):241-7 [17709687.001]
  • [Cites] Am J Health Syst Pharm. 2007 Nov 15;64(22):2359-63 [17989446.001]
  • [Cites] Clin Infect Dis. 2008 Jan 15;46 Suppl 1:S12-8 [18177217.001]
  • [Cites] Clin Infect Dis. 2008 Jan 15;46 Suppl 1:S32-42 [18177219.001]
  • [Cites] J Bacteriol. 2008 Apr;190(7):2505-12 [18245298.001]
  • [Cites] Crit Care Clin. 2008 Apr;24(2):279-91, viii [18361946.001]
  • [Cites] J Med Microbiol. 2008 Jun;57(Pt 6):717-24 [18480328.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jun;52(6):2190-5 [18391047.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jul;52(7):2403-6 [18443120.001]
  • [Cites] Am J Gastroenterol. 2008 Sep;103(9):2308-13 [18702653.001]
  • [Cites] N Engl J Med. 2008 Oct 30;359(18):1932-40 [18971494.001]
  • [Cites] N Engl J Med. 1999 Nov 25;341(22):1645-51 [10572152.001]
  • [Cites] N Engl J Med. 2000 Feb 10;342(6):390-7 [10666429.001]
  • [Cites] Clin Infect Dis. 2000 Oct;31(4):1012-7 [11049785.001]
  • [Cites] Clin Microbiol Infect. 2001 Aug;7(8):442-6 [11591209.001]
  • [Cites] Clin Infect Dis. 2002 Feb 1;34(3):346-53 [11774082.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):363-72 [11882758.001]
  • [Cites] Infect Control Hosp Epidemiol. 2002 Dec;23(12 Suppl):S3-40 [12515399.001]
  • [Cites] J Hosp Infect. 2003 Jul;54(3):243-5 [12855243.001]
  • [Cites] Scand J Infect Dis. 2003;35(6-7):365-7 [12953945.001]
  • [Cites] Dtsch Med Wochenschr. 2003 Nov 28;128(48):2531-3 [14648435.001]
  • [Cites] Gut. 2004 May;53(5):673-7 [15082585.001]
  • [Cites] Gastroenterology. 1978 Nov;75(5):778-82 [700321.001]
  • [Cites] Lancet. 1978 Apr 15;1(8068):802-3 [85818.001]
  • [Cites] Gastroenterology. 1981 Jul;81(1):5-9 [7239125.001]
  • [Cites] Dis Colon Rectum. 1982 Jul-Aug;25(5):478-82 [7094787.001]
  • [Cites] J Infect Dis. 1983 Jul;148(1):93-100 [6886489.001]
  • [Cites] Lancet. 1983 Nov 5;2(8358):1043-6 [6138597.001]
  • [Cites] Infection. 1985 May-Jun;13(3):97-101 [4030111.001]
  • [Cites] Gastroenterology. 1987 Aug;93(2):273-9 [3596162.001]
  • [Cites] N Engl J Med. 1989 Jan 26;320(4):204-10 [2911306.001]
  • [Cites] Ann Intern Med. 1989 Feb 15;110(4):255-7 [2643913.001]
  • (PMID = 20697257.001).
  • [ISSN] 1538-2990
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL084489-03; United States / NHLBI NIH HHS / HL / R01 HL084489-05
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 93
  • [Other-IDs] NLM/ NIHMS221674; NLM/ PMC2935936
  •  go-up   go-down


6. |||||||||. 89%  Sun X, Savidge T, Feng H: The enterotoxicity of Clostridium difficile toxins. Toxins (Basel); 2010 Jul;2(7):1848-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The enterotoxicity of Clostridium difficile toxins.
  • The major virulence factors of Clostridium difficile infection (CDI) are two large exotoxins A (TcdA) and B (TcdB).
  • Both purified TcdA and TcdB are capable of inducing the pathophysiology of CDI, although most studies have focused on TcdA. C. difficile toxins exert a wide array of biological activities by acting directly on intestinal epithelial cells.
  • [MeSH-minor] Animals. Clostridium Infections / etiology. Clostridium difficile / pathogenicity. Disease Models, Animal. Humans. Protein Structure, Tertiary

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2009 Oct 16;284(42):28713-9 [19692332.001]
  • [Cites] PLoS Pathog. 2009 Oct;5(10):e1000626 [19834554.001]
  • [Cites] Exp Cell Res. 2009 Nov 15;315(19):3336-44 [19481075.001]
  • [Cites] J Infect Dis. 2010 Feb 1;201(3):428-34 [20039803.001]
  • [Cites] J Lipid Mediat Cell Signal. 1995 Mar;11(2):133-43 [7540097.001]
  • [Cites] Gastroenterology. 1995 Aug;109(2):348-54 [7615182.001]
  • [Cites] Curr Opin Struct Biol. 1995 Oct;5(5):622-35 [8574698.001]
  • [Cites] J Biol Chem. 1996 Mar 29;271(13):7324-9 [8631752.001]
  • [Cites] Gut. 1996 Mar;38(3):337-47 [8675084.001]
  • [Cites] Gastroenterology. 1996 Aug;111(2):409-18 [8690206.001]
  • [Cites] J Lab Clin Med. 1996 Aug;128(2):134-45 [8765209.001]
  • [Cites] Trends Microbiol. 1996 Oct;4(10):375-82 [8899962.001]
  • [Cites] Glycobiology. 1996 Sep;6(6):599-609 [8922955.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):328-34 [9089662.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4788-93 [9114070.001]
  • [Cites] Gastroenterology. 1997 Jun;112(6):1887-94 [9178681.001]
  • [Cites] Infect Immun. 1997 Jul;65(7):2740-6 [9199444.001]
  • [Cites] Toxicon. 1997 May;35(5):743-52 [9203299.001]
  • [Cites] Immunology. 1997 Jun;91(2):281-8 [9227329.001]
  • [Cites] J Biol Chem. 1997 Sep 5;272(36):22373-6 [9278382.001]
  • [Cites] Am J Physiol. 1997 Dec;273(6 Pt 1):G1333-40 [9435559.001]
  • [Cites] Am J Physiol. 1998 Jan;274(1 Pt 1):G196-202 [9458790.001]
  • [Cites] Annu Rev Med. 1998;49:375-90 [9509270.001]
  • [Cites] J Clin Invest. 1998 Apr 15;101(8):1547-50 [9541482.001]
  • [Cites] Biochemistry. 1998 Apr 14;37(15):5296-304 [9548761.001]
  • [Cites] Infect Immun. 1982 Mar;35(3):1147-50 [7068215.001]
  • [Cites] Infect Immun. 2006 Oct;74(10):6006-10 [16988280.001]
  • [Cites] Infect Immun. 2006 Nov;74(11):6339-47 [16966409.001]
  • [Cites] Ann Intern Med. 2006 Nov 21;145(10):758-64 [17116920.001]
  • [Cites] Annu Rev Immunol. 1991;9:271-96 [1910679.001]
  • [Cites] Gastroenterology. 1992 Feb;102(2):416-23 [1732112.001]
  • [Cites] Int J Infect Dis. 2007 Jan;11(1):5-10 [16857405.001]
  • [Cites] Infect Immun. 2007 Feb;75(2):801-9 [17145947.001]
  • [Cites] J Med Microbiol. 2007 Mar;56(Pt 3):329-35 [17314362.001]
  • [Cites] Glycobiology. 2007 Apr;17(4):15R-22R [17237138.001]
  • [Cites] J Biol Chem. 2007 Mar 23;282(12):9029-41 [17220295.001]
  • [Cites] Nature. 2007 Mar 22;446(7134):415-9 [17334356.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2422-37 [17570216.001]
  • [Cites] Am J Infect Control. 2007 Jun;35(5):315-8 [17577478.001]
  • [Cites] Clin Infect Dis. 2007 Jul 15;45(2):222-7 [17578783.001]
  • [Cites] Pharmacotherapy. 2007 Jul;27(7):1029-39 [17594209.001]
  • [Cites] Clin Infect Dis. 2007 Aug 1;45(3):302-7 [17599306.001]
  • [Cites] Infect Immun. 2007 Aug;75(8):3868-76 [17517880.001]
  • [Cites] Intern Med J. 2007 Aug;37(8):561-8 [17640189.001]
  • [Cites] J Bacteriol. 2007 Oct;189(20):7290-301 [17693517.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):35222-31 [17901056.001]
  • [Cites] BMC Infect Dis. 2008;8:7 [18218089.001]
  • [Cites] Infect Immun. 2008 Mar;76(3):1170-8 [18160482.001]
  • [Cites] Diagn Microbiol Infect Dis. 2008 Apr;60(4):333-7 [18082994.001]
  • [Cites] FEMS Microbiol Rev. 2008 May;32(3):541-55 [18397287.001]
  • [Cites] Trends Microbiol. 2008 May;16(5):222-9 [18394902.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Jan;23(1):4-9 [17133077.001]
  • [Cites] Infect Immun. 1998 Jun;66(6):2660-5 [9596731.001]
  • [Cites] J Antimicrob Chemother. 1998 May;41 Suppl C:13-9 [9630370.001]
  • [Cites] J Immunol. 1998 Jun 15;160(12):6039-45 [9637520.001]
  • [Cites] Mol Gen Genet. 1998 May;258(3):222-32 [9645428.001]
  • [Cites] Infect Immun. 1998 Nov;66(11):5462-9 [9784558.001]
  • [Cites] Nephrol Dial Transplant. 1998 Nov;13(11):2842-6 [9829488.001]
  • [Cites] Am J Physiol. 1999 Feb;276(2 Pt 1):G485-90 [9950823.001]
  • [Cites] Am J Physiol. 1999 Mar;276(3 Pt 1):C717-24 [10070000.001]
  • [Cites] J Clin Invest. 1999 Mar;103(6):843-9 [10079105.001]
  • [Cites] Int J Mol Med. 1999 Sep;4(3):223-30 [10425270.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 2004;152:23-47 [15449191.001]
  • [Cites] Science. 2005 Jan 14;307(5707):254-8 [15653504.001]
  • [Cites] Infect Immun. 2005 Mar;73(3):1625-34 [15731062.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):764-70 [15765411.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):1002-11 [15825081.001]
  • [Cites] Clin Microbiol Rev. 2005 Apr;18(2):247-63 [15831824.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1306-16 [15887113.001]
  • [Cites] J Infect Dis. 2005 Jun 15;191(12):2090-6 [15897995.001]
  • [Cites] Gastroenterology. 2008 Jun;134(7):2049-58 [18435932.001]
  • [Cites] Vaccine. 2008 Jun 25;26(27-28):3404-9 [18502001.001]
  • [Cites] Infect Immun. 2008 Jul;76(7):2862-71 [18411291.001]
  • [Cites] Clin Exp Immunol. 2008 Sep;153(3):439-47 [18505424.001]
  • [Cites] J Appl Toxicol. 2008 Oct;28(7):849-57 [18381687.001]
  • [Cites] FEBS Lett. 2008 Nov 12;582(27):3751-6 [18848548.001]
  • [Cites] Gastroenterology. 2008 Dec;135(6):1984-92 [18848941.001]
  • [Cites] Gut. 2009 Jan;58(1):34-40 [18824554.001]
  • [Cites] J Mol Med (Berl). 2009 Feb;87(2):169-80 [18985311.001]
  • [Cites] Nature. 2009 Apr 30;458(7242):1176-9 [19252482.001]
  • [Cites] Microb Pathog. 2009 Jun;46(6):298-305 [19324080.001]
  • [Cites] J Microbiol Methods. 2009 Jul;78(1):97-100 [19393695.001]
  • [Cites] J Biol Chem. 2009 Aug 14;284(33):21934-40 [19553670.001]
  • [Cites] Infect Immun. 2009 Sep;77(9):3661-9 [19564382.001]
  • [Cites] J Clin Microbiol. 2003 Nov;41(11):5227-32 [14605169.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):3018-25 [14978106.001]
  • [Cites] J Gen Physiol. 2004 May;123(5):491-504 [15078917.001]
  • [Cites] J Infect Dis. 2004 May 1;189(9):1585-9 [15116293.001]
  • [Cites] J Clin Microbiol. 2004 May;42(5):1933-9 [15131151.001]
  • [Cites] J Infect Dis. 2004 Jun 1;189(11):2110-9 [15143480.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8503-8 [15159534.001]
  • [Cites] Heart Lung. 2004 Jul-Aug;33(4):265-8 [15252417.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Oct;48(10):3975-9 [15388461.001]
  • [Cites] J Infect Dis. 1978 Apr;137(4):464-75 [649990.001]
  • [Cites] Infect Immun. 1978 May;20(2):526-9 [669810.001]
  • [Cites] Infect Immun. 1979 Jan;23(1):31-3 [422233.001]
  • [Cites] Gut. 1979 Jun;20(6):467-75 [468072.001]
  • [Cites] Gut. 1986 Jan;27(1):78-85 [3949240.001]
  • [Cites] Infect Immun. 1986 Sep;53(3):573-81 [3744552.001]
  • [Cites] Pathol Biol (Paris). 1986 Nov;34(9):977-82 [3543815.001]
  • [Cites] Zhongguo Yao Li Xue Bao. 1986 Sep;7(5):448-53 [2954421.001]
  • [Cites] Gastroenterology. 1987 Aug;93(2):273-9 [3596162.001]
  • [Cites] J Med Microbiol. 1987 Aug;24(1):41-52 [3612743.001]
  • [Cites] Infect Immun. 1987 Dec;55(12):2984-92 [3679541.001]
  • [Cites] Infect Immun. 1988 Mar;56(3):582-8 [3343050.001]
  • [Cites] J Clin Invest. 1988 Jun;81(6):1741-5 [2838520.001]
  • [Cites] J Clin Invest. 1988 Nov;82(5):1516-24 [3141478.001]
  • [Cites] Clin Microbiol Rev. 1988 Jan;1(1):1-18 [3144429.001]
  • [Cites] Microb Pathog. 1987 Jun;2(6):455-63 [3148814.001]
  • [Cites] Gastroenterology. 1998 May;114(5):956-64 [9558284.001]
  • [Cites] Infect Immun. 1998 May;66(5):2018-25 [9573084.001]
  • [Cites] Clin Infect Dis. 1998 May;26(5):1027-34; quiz 1035-6 [9597221.001]
  • [Cites] Rev Infect Dis. 1979 Mar-Apr;1(2):386-97 [549190.001]
  • [Cites] Gut. 1980 Jun;21(6):493-9 [6776012.001]
  • [Cites] Infect Immun. 1981 Dec;34(3):1036-43 [7333662.001]
  • [Cites] Infect Immun. 1991 Jan;59(1):73-8 [1670930.001]
  • [Cites] Infect Immun. 1982 May;36(2):822-9 [7085078.001]
  • [Cites] Lab Anim Sci. 1982 Jun;32(3):253-7 [6285077.001]
  • [Cites] J Infect Dis. 1982 Dec;146(6):727-33 [7142747.001]
  • [Cites] Pediatr Infect Dis. 1982 Sep-Oct;1(5):336-8 [7155966.001]
  • [Cites] Infect Immun. 1983 Mar;39(3):1368-76 [6840842.001]
  • [Cites] J Infect Dis. 1983 Sep;148(3):606 [6619580.001]
  • [Cites] Infect Immun. 1983 Nov;42(2):480-6 [6642638.001]
  • [Cites] Biochim Biophys Acta. 1983 Dec 19;763(4):383-92 [6652117.001]
  • [Cites] J Clin Microbiol. 1984 Jan;19(1):77-8 [6690469.001]
  • [Cites] Acta Pathol Microbiol Immunol Scand B. 1983 Dec;91(6):395-400 [6673499.001]
  • [Cites] Arch Dis Child. 1984 May;59(5):466-72 [6732277.001]
  • [Cites] Infect Immun. 1985 Feb;47(2):349-52 [3917975.001]
  • [Cites] Appl Environ Microbiol. 1985 Jan;49(1):250-2 [3977313.001]
  • [Cites] Prog Clin Biol Res. 1985;181:203-6 [4022975.001]
  • [Cites] FEMS Microbiol Lett. 2005 May 15;246(2):199-205 [15899406.001]
  • [Cites] J Biol Chem. 2005 Jun 3;280(22):21237-45 [15767259.001]
  • [Cites] Postgrad Med J. 2005 Jun;81(956):367-9 [15937201.001]
  • [Cites] J Mol Biol. 2005 Sep 2;351(5):973-81 [16054646.001]
  • [Cites] Cell Microbiol. 2005 Dec;7(12):1798-810 [16309465.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2442-9 [16322602.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2433-41 [16322603.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1875-88 [16344056.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18373-8 [16344467.001]
  • [Cites] Life Sci. 2006 Jan 25;78(9):920-5 [16185718.001]
  • [Cites] J Infect Dis. 2006 Apr 15;193(8):1143-50 [16544255.001]
  • [Cites] J Biol Chem. 2006 Apr 21;281(16):10808-15 [16513641.001]
  • [Cites] Vet Pathol. 2006 May;43(3):225-40 [16672570.001]
  • [Cites] Nat Struct Mol Biol. 2006 May;13(5):460-1 [16622409.001]
  • [Cites] Scand J Immunol. 2006 Jun;63(6):453-60 [16764699.001]
  • [Cites] J Immunol. 2006 Jul 15;177(2):1214-20 [16818780.001]
  • [Cites] J Immunol. 2006 Sep 1;177(5):3355-61 [16920976.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14176-81 [16966605.001]
  • [Cites] Infect Immun. 1991 Mar;59(3):1192-5 [1900059.001]
  • [Cites] Infect Immun. 1991 Apr;59(4):1223-30 [1900806.001]
  • [Cites] Infect Immun. 1991 Oct;59(10):3659-66 [1910012.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5183-91 [10553038.001]
  • [Cites] N Engl J Med. 2000 Feb 10;342(6):390-7 [10666429.001]
  • [Cites] J Immunol. 2000 Feb 15;164(4):1952-60 [10657645.001]
  • [Cites] Infect Immun. 2000 Apr;68(4):2161-6 [10722615.001]
  • [Cites] Infect Immun. 2000 May;68(5):2470-4 [10768933.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):1147-56 [10772660.001]
  • [Cites] J Clin Microbiol. 2000 Jun;38(6):2386-8 [10835010.001]
  • [Cites] J Clin Immunol. 2000 May;20(3):151-60 [10941822.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Sep;44(9):2254-8 [10952564.001]
  • [Cites] J Med Microbiol. 2008 Jun;57(Pt 6):765-70 [18480335.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jun;52(6):2190-5 [18391047.001]
  • [Cites] Vaccine. 2010 Jan 22;28(4):965-9 [19941990.001]
  • [Cites] J Mol Biol. 2010 Mar 12;396(5):1260-70 [20070948.001]
  • [Cites] Gastroenterology. 2010 Jul;139(1):259-69.e3 [20347817.001]
  • [Cites] Gastroenterology. 2010 Aug;139(2):542-52, 552.e1-3 [20398664.001]
  • [Cites] J Infect Dis. 2001 Sep 1;184(5):648-52 [11474431.001]
  • [Cites] J Clin Invest. 1992 Sep;90(3):822-9 [1325998.001]
  • [Cites] Infect Immun. 1992 Oct;60(10):4192-9 [1398930.001]
  • [Cites] Infect Immun. 1992 Nov;60(11):4633-9 [1398977.001]
  • [Cites] Crit Rev Immunol. 1992;12(1-2):17-46 [1418604.001]
  • [Cites] Clin Infect Dis. 1993 Jun;16 Suppl 4:S219-27 [8324123.001]
  • [Cites] Gastroenterol Clin North Am. 1993 Sep;22(3):623-37 [8406734.001]
  • [Cites] Am J Physiol. 1993 Nov;265(5 Pt 2):F736-42 [8238556.001]
  • [Cites] N Engl J Med. 1994 Jan 27;330(4):257-62 [8043060.001]
  • [Cites] Cell. 1994 Jan 28;76(2):301-14 [7507411.001]
  • [Cites] J Clin Invest. 1994 Mar;93(3):1257-65 [7907603.001]
  • [Cites] Gastroenterology. 1994 Sep;107(3):657-65 [7915699.001]
  • [Cites] Diagn Microbiol Infect Dis. 1994 Apr;18(4):205-9 [7924215.001]
  • [Cites] Am J Physiol. 1994 Dec;267(6 Pt 1):G991-7 [7810667.001]
  • [Cites] Microb Pathog. 1994 Jul;17(1):1-12 [7861949.001]
  • [Cites] J Immunol. 1995 May 15;154(10):5418-25 [7730643.001]
  • [Cites] J Clin Invest. 1995 May;95(5):2004-11 [7738167.001]
  • [Cites] Nature. 1995 Jun 8;375(6531):500-3 [7777059.001]
  • [Cites] Ann Intern Med. 2001 Sep 18;135(6):434-8 [11560456.001]
  • [Cites] J Biol Chem. 2002 Feb 8;277(6):4247-54 [11729192.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1048-57 [11910356.001]
  • [Cites] Cell Microbiol. 2002 Jul;4(7):425-34 [12102688.001]
  • [Cites] Microbiol Immunol. 2002;46(5):333-42 [12139393.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):505-15 [12145804.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2002 Oct;283(4):L830-8 [12225960.001]
  • [Cites] Infect Immun. 2002 Oct;70(10):5770-8 [12228307.001]
  • [Cites] J Infect Dis. 2002 Nov 15;186(10):1438-47 [12404159.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):7956-63 [12496290.001]
  • [Cites] Mediators Inflamm. 2003 Feb;12(1):3-8 [12745542.001]
  • [Cites] Intensive Care Med. 2003 Jun;29(6):1030 [12734650.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):413-20 [12891543.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2003 Nov;285(5):G1049-55 [12801886.001]
  • [Cites] J Biol Chem. 2003 Nov 7;278(45):44535-41 [12941936.001]
  • [Cites] Microb Pathog. 1986 Aug;1(4):373-85 [3508493.001]
  • [Cites] Gastroenterology. 1989 Nov;97(5):1186-92 [2551764.001]
  • [Cites] Rev Infect Dis. 1990 Jan-Feb;12 Suppl 2:S185-91 [2406871.001]
  • [Cites] J Med Microbiol. 1990 Mar;31(3):169-74 [2156075.001]
  • [Cites] Am J Physiol. 1990 Aug;259(2 Pt 1):G165-72 [2116728.001]
  • [Cites] Am J Pathol. 1990 Nov;137(5):1103-11 [2240161.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Oct 14;277(1):43-6 [11027636.001]
  • [Cites] Shock. 2000 Dec;14(6):629-34 [11131913.001]
  • [Cites] Infect Immun. 2001 Feb;69(2):988-95 [11159994.001]
  • [Cites] Scand J Infect Dis. 2001;33(1):69-70 [11234983.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Feb;280(2):G178-83 [11208538.001]
  • [Cites] FEMS Microbiol Lett. 2001 May 1;198(2):171-6 [11430410.001]
  • (PMID = 22069662.001).
  • [ISSN] 2072-6651
  • [Journal-full-title] Toxins
  • [ISO-abbreviation] Toxins (Basel)
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K01 DK076549; United States / NIAID NIH HHS / AI / R01 AI088748; United States / NIDDK NIH HHS / DK / R01 DK084509
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Bacterial Toxins; 0 / Clostridium difficile lethal toxin B; 0 / Enterotoxins; 0 / tcdA protein, Clostridium difficile
  • [Other-IDs] NLM/ PMC3153265
  • [Keywords] NOTNLM ; Clostridium difficile / enterotoxicity / toxin A (TcdA) / toxin B (TcdB)
  • [General-notes] NLM/ Original DateCompleted: 20111110
  •  go-up   go-down


7. ||||||.... 60%  Cooper IF, Siadaty MS: 'Steroids' associated with 'Clostridium Difficile Disorder': Top Publications. BioMedLib Review; Steroid;ClostridiumDifficileDisorder:705822018. ISSN: 2331-5717. 2014/4/28
PDF icon [Fulltext service] Download fulltext PDF of this article.

  • [Title] 'Steroids' associated with 'Clostridium Difficile Disorder': Top Publications.
  • Background: There are articles published each month which present 'steroid' for 'clostridium difficile disorder'.
  • Shin S et al: Evaluation of the Xpert Clostridium difficile assay for the diagnosis of Clostridium difficile infection.
  • Pitts AC et al: Structural insight into the Clostridium difficile ethanolamine utilisation microcompartment.
  • Di Bella S et al: Clostridium difficile infection in the elderly.
  • Aubry A et al: Modulation of toxin production by the flagellar regulon in Clostridium difficile.
  • Kuntz JL et al: Clostridium difficile infection, Colorado and the northwestern United States, 2007.
  • Dubberke ER et al: Burden of Clostridium difficile on the healthcare system.
  • Tyrrell KL et al: Evaluation of cycloserine-cefoxitin fructose agar (CCFA), CCFA with horse blood and taurocholate, and cycloserine-cefoxitin mannitol broth with taurocholate and lysozyme for recovery of Clostridium difficile isolates from fecal samples.
  • Brazier JS: Clostridium difficile: the anaerobe that made the grade.
  • Foster NF et al: Improved recovery of Clostridium difficile spores with the incorporation of synthetic taurocholate in cycloserine-cefoxitin-fructose agar (CCFA).
  • Blanco JL et al: Is the prevalence of Clostridium difficile in animals underestimated?.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2014 Siadaty and Cooper; licensee BioMedLib LLC.
  • (UID = 705822018.001).
  • [ISSN] 2331-5717
  • [Journal-full-title] BioMedLib Review
  • [Language] eng
  • [Publication-type] Review
  • [Publication-country] UNITED STATES
  •  go-up   go-down


8. |||||||||. 127%  Rupnik M: Clostridium difficile toxinotyping. Methods Mol Biol; 2010;646:67-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium difficile toxinotyping.
  • Clostridium difficile shows considerable variability in the PaLoc region encoding two main virulence factors, toxins TcdA and TcdB.
  • [MeSH-major] Clostridium difficile / classification. Clostridium difficile / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20597003.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Bacterial Toxins; 0 / Enterotoxins; 0 / tcdA protein, Clostridium difficile; 0 / toxB protein, Clostridium difficile
  •  go-up   go-down


9. |||||||||. 125%  Curry S: Clostridium difficile. Clin Lab Med; 2010 Mar;30(1):329-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium difficile.
  • Clostridium difficile has re-emerged as a major hospital-acquired infection since 2001.
  • The importance of C difficile acquired outside the hospital environment remains an unknown factor and awaits further epidemiologic investigation.
  • This article discusses the changing epidemiology, clinical presentation, and pathogenesis of C difficile infection and highlights the ongoing challenges of laboratory diagnosis, treatment, and disease relapse.
  • [MeSH-minor] Animals. Clostridium difficile / immunology. Clostridium difficile / isolation & purification. Humans. Prognosis. Recurrence

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • COS Scholar Universe. author profiles.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20513554.001).
  • [ISSN] 1557-9832
  • [Journal-full-title] Clinics in laboratory medicine
  • [ISO-abbreviation] Clin. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 105
  •  go-up   go-down


10. |||||||||. 102%  Metcalf DS, Costa MC, Dew WM, Weese JS: Clostridium difficile in vegetables, Canada. Lett Appl Microbiol; 2010 Nov;51(5):600-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium difficile in vegetables, Canada.
  • BACKGROUND: Clostridium difficile is an important gastrointestinal pathogen of humans and animals.
  • It has been isolated from various foods, including meat and ready-to-eat salads, and concern has been expressed regarding food as a possible source of human C. difficile infection (CDI).
  • AIMS: We sought to isolate C. difficile from a variety of vegetables obtained from local grocery stores and to characterize these isolates.
  • RESULTS: Clostridium difficile was isolated from 4.5% (5/111) of retail vegetables.
  • CONCLUSIONS: Contamination of vegetables with CDI-associated isolates can occur and although the implications for food safety practices remain elusive, the presence of toxigenic isolates suggests vegetables could be a source of C. difficile in humans.
  • [MeSH-major] Clostridium difficile / isolation & purification. Enterocolitis, Pseudomembranous / microbiology. Vegetables / microbiology


11. |||||||||. 101%  Efron PA, Mazuski JE: Clostridium difficile colitis. Surg Clin North Am; 2009 Apr;89(2):483-500, x
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium difficile colitis.
  • Clostridium difficile is the most common cause of infectious diarrhea in hospitalized patients.
  • Its effects are mediated by C difficile toxins A and B.
  • Although oral metronidazole and oral vancomycin can be used to treat C difficile-associated disease, intraluminal vancomycin is preferable for more severe C difficile colitis.
  • [MeSH-major] Clostridium Infections. Clostridium difficile. Cross Infection. Enterocolitis, Pseudomembranous


12. |||||||||. 101%  Bujanda L, Cosme A: [Clostridium-difficile-associated diarrhea]. Gastroenterol Hepatol; 2009 Jan;32(1):48-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clostridium-difficile-associated diarrhea].
  • [Transliterated title] Diarrea asociada a Clostridium difficile.
  • Clostridium difficile is the most frequent cause of nosocomial diarrhea and is a significant cause of morbidity among hospitalized patients.
  • [MeSH-major] Clostridium difficile / physiology. Diarrhea / microbiology. Enterocolitis, Pseudomembranous / microbiology


13. |||||||||. 100%  Wiggelinkhuizen M, Gerrits MA: [Clostridium difficile-induced necrotizing enteritis]. Ned Tijdschr Geneeskd; 2011;155(49):A2414
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clostridium difficile-induced necrotizing enteritis].
  • [Transliterated title] Necrotiserende enteritis door Clostridium difficile.
  • BACKGROUND: Clostridium difficile infection usually manifests as pseudomembranous colitis.
  • Infection of the small intestine is rare. C. difficile enteritis has a high mortality rate due to secondary enteric necrosis and perforation.
  • CASE DESCRIPTION: We describe an 87-year-old woman with abdominal pain, who died from necrotizing enteritis due to a C. difficile infection.
  • This is the first described case of small bowel involvement in the absence of known risk factors for C. difficile enteritis, i.e. bowel surgery and recent use of antibiotics.
  • The described patient was using immunosuppressants, which in this case could have been a risk factor for small bowel colonization with C. difficile.
  • CONCLUSION: In clinical practice it is important to be prepared for C. difficile infection, as early treatment of this infection will strongly improve the prognosis.
  • Identification of patients at an increased risk of C. difficile infection is of great value in this respect.
  • [MeSH-major] Clostridium Infections / complications. Clostridium difficile / pathogenicity. Enteritis / etiology

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22166175.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


14. |||||||||. 100%  Ramos Martínez A, Romero Pizarro Y, Martínez Arrieta F, Balandín Moreno B, Múñez Rubio E, Cuiñas León K, Sánchez Romero I, Cantos López de Ibargüen B, Asensio Vegas A: [Clostridium difficile enteritis]. Gastroenterol Hepatol; 2011 Oct;34(8):539-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clostridium difficile enteritis].
  • [Transliterated title] Enteritis por Clostridium difficile.
  • INTRODUCTION: Clostridium difficile infection of the small intestine is infrequent.
  • METHOD: We present the first case of C. difficile enteritis (CDE) diagnosed in Spain and provide a review of the literature.
  • [MeSH-major] Clostridium difficile / isolation & purification. Enteritis / microbiology. Enterocolitis, Pseudomembranous / diagnosis. Opportunistic Infections / microbiology. Postoperative Complications / microbiology


15. |||||||||. 99%  Pant C, Madonia PN, Jordan P, Manas K, Bass P 3rd: Harbingers for Clostridium difficile-associated diarrhea. J Investig Med; 2009 Jan;57(1):40-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Harbingers for Clostridium difficile-associated diarrhea.
  • PURPOSE: : Recent research has recognized surrogate markers for Clostridium difficile-associated diarrhea (CDAD).
  • METHODS: : We undertook a retrospective review of inpatients at our institution that were diagnosed with nosocomial diarrhea and subsequently had a stool sample sent for C. difficile toxins A and B.
  • RESULTS: : A total of 77 C. difficile-positive patients and 91 C. difficile-negative patients were studied.
  • [MeSH-major] Clostridium Infections / diagnosis. Clostridium difficile. Diarrhea / microbiology

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • Genetic Alliance. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - Diarrhea.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19092680.001).
  • [ISSN] 1081-5589
  • [Journal-full-title] Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  • [ISO-abbreviation] J. Investig. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


16. |||||||||. 99%  Cartman ST, Heap JT, Kuehne SA, Cockayne A, Minton NP: The emergence of 'hypervirulence' in Clostridium difficile. Int J Med Microbiol; 2010 Aug;300(6):387-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The emergence of 'hypervirulence' in Clostridium difficile.
  • The impact of Clostridium difficile-associated disease (CDAD) in healthcare settings throughout the developed world is considerable in terms of mortality, morbidity, and disease management.
  • The physiological factors responsible for the rapid emergence of hypervirulent C. difficile strains remain unclear.
  • However, the contribution of these and other as yet unidentified factors to the rapid spread of certain C. difficile variants (e.g., ribotypes 027 and 078) remains unclear at present.
  • The advent of ClosTron technology means that it is now possible to construct genetically stable isogenic mutants of C. difficile and carry out reverse genetic studies to elucidate the role of specific gene loci in causing disease.
  • [MeSH-major] Clostridium difficile / pathogenicity. Enterocolitis, Pseudomembranous / epidemiology. Evolution, Molecular. Virulence Factors / genetics

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • MedlinePlus Health Information. consumer health - Clostridium Difficile Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20547099.001).
  • [ISSN] 1618-0607
  • [Journal-full-title] International journal of medical microbiology : IJMM
  • [ISO-abbreviation] Int. J. Med. Microbiol.
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/D522797/1; United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/F003390/1; United Kingdom / Biotechnology and Biological Sciences Research Council / / BD/D522289/1; United Kingdom / Medical Research Council / / G0601176
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Virulence Factors
  •  go-up   go-down


17. |||||||||. 99%  Hopman NE, Keessen EC, Harmanus C, Sanders IM, van Leengoed LA, Kuijper EJ, Lipman LJ: Acquisition of Clostridium difficile by piglets. Vet Microbiol; 2011 Apr 21;149(1-2):186-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquisition of Clostridium difficile by piglets.
  • Clostridium difficile is recognized as an important cause of nosocomial diarrhoea in humans especially in association with administration of antibiotics.
  • In pigs, C. difficile can cause neonatal enteritis and can be isolated from faeces from both diseased and healthy animals.
  • The presented prospective study describes how soon C. difficile can be isolated from newborn piglets after normal parturition and how C. difficile spreads within a pig farm.
  • Six sows, their farrowing crates and their litters at one farm were sampled until C. difficile was found in all piglets.
  • Within 48 h after birth, all 71 piglets became positive for C. difficile (two piglets were already positive within 1h post partum), all sows became positive within 113 h after parturition and the farrowing crates were found intermittently positive. C. difficile could also be detected in air samples and in samples of teats of the sows.
  • Twenty-one C. difficile ribotype 078 isolates, found at the farm, were further analyzed by MLVA (multiple-locus variable-number tandem repeat analysis) and belonged to one clonal complex, except one isolate.
  • To be sure that piglets were not born already infected with C. difficile ribotype 078, 38 caesarean derived piglets were sampled immediately after surgery.
  • All piglets tested negative at delivery and stayed negative for C. difficile ribotype 078 during the 21 days in which they were kept in sterile incubators.
  • This study shows that C. difficile ribotype 078 spreads easily between sows, piglets and the environment.
  • Vertical transmission of C. difficile ribotype 078 was not found and is very unlikely to occur.
  • [MeSH-major] Clostridium difficile / isolation & purification. Enterocolitis, Pseudomembranous / veterinary. Swine / microbiology. Swine Diseases / microbiology

  • MedlinePlus Health Information. consumer health - Clostridium Difficile Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 21111541.001).
  • [ISSN] 1873-2542
  • [Journal-full-title] Veterinary microbiology
  • [ISO-abbreviation] Vet. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


18. |||||||||. 95%  Al-Najjar A, Al-Rawahi GN, Hoang LM, Kollmann TR: Clostridium difficile vertebral osteomyelitis. Pediatr Infect Dis J; 2013 Sep;32(9):1030-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium difficile vertebral osteomyelitis.
  • Clostridium difficile is the most common cause of antibiotic-associated diarrhea, and it occasionally causes extraintestinal infections.
  • We present a case of C. difficile-associated diarrhea that led to vertebral osteomyelitis associated with hardware.
  • The osteomyelitis became symptomatic 2 years after the initial diarrheal event. C. difficile recovered from internal hardware sites cannot simply be regarded as a contaminant but should be treated.
  • [MeSH-major] Clostridium Infections / diagnosis. Clostridium difficile / isolation & purification. Osteomyelitis / diagnosis. Spinal Diseases / diagnosis


19. |||||||||. 94%  Mäkelä J, Takala H, Klintrup K, Syrjälä H, Rautio T: [Fulminant Clostridium difficile colitis]. Duodecim; 2013;129(16):1681-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fulminant Clostridium difficile colitis].
  • [Transliterated title] Fulminantin Clostridium difficilen aiheuttama koliitti--milloin kirurginen hoito on aiheellinen?
  • Clostridium difficile is a common cause of nosocomial diarrhea and it's most difficult Fulminant form is increasing in prevalence and severity in hospitalized patients.
  • [MeSH-major] Clostridium Infections / therapy. Colitis / therapy. Cross Infection / therapy. Enterocolitis, Pseudomembranous / therapy

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24069637.001).
  • [ISSN] 0012-7183
  • [Journal-full-title] Duodecim; lääketieteellinen aikakauskirja
  • [ISO-abbreviation] Duodecim
  • [Language] fin
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Finland
  •  go-up   go-down


20. |||||||||. 94%  Lipovsek S, Leitinger G, Rupnik M: Ultrastructure of Clostridium difficile colonies. Anaerobe; 2013 Dec;24:66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrastructure of Clostridium difficile colonies.
  • The ultrastructural colony architecture of six Clostridium difficile strains belonging to four different ribotypes (001, 027, 078/126 and 036) was studied by scanning electron microscopy (SEM).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2013 Elsevier Ltd. All rights reserved.
  • (PMID = 24120350.001).
  • [ISSN] 1095-8274
  • [Journal-full-title] Anaerobe
  • [ISO-abbreviation] Anaerobe
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Keywords] NOTNLM ; Bacterial colony patterns / Biofilm / Clostridium difficile / Motility / Scanning electron microscopy / Sporulation
  •  go-up   go-down


21. |||||||||. 92%  Allen UD, Canadian Paediatric Society, Infectious Diseases and Immunization Committee: Clostridium difficile in paediatric populations. Paediatr Child Health; 2014 Jan;19(1):43-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium difficile in paediatric populations.
  • An increase in Clostridium difficile infection incidence has been observed among hospitalized children in the United States.
  • The present statement, targeted at clinicians caring for infants and children in community and institutional settings, summarizes the relevant information relating to the role of C difficile in childhood diarrhea and provides recommendations for diagnosis, prevention and treatment.
  • The relationship between age and disease severity in children with a newly emergent and more fluoroqinolone-resistant strain of C difficile (North American Pulse-field type-1 [NAP1]) remains unknown.
  • This statement replaces a previous Canadian Paediatric Society position statement on C difficile published in 2000.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24627655.001).
  • [ISSN] 1205-7088
  • [Journal-full-title] Paediatrics & child health
  • [ISO-abbreviation] Paediatr Child Health
  • [Language] eng; fre
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3938221 [Available on 01/01/15]
  • [Keywords] NOTNLM ; CDI / Colitis / Diarrhea / Immunocompromise / Megacolon / Metronidazole / NAP1 / Vancomycin
  •  go-up   go-down


22. |||||||||. 90%  Hussain HA, Roberts AP, Whalan R, Mullany P: Transposon mutagenesis in Clostridium difficile. Methods Mol Biol; 2010;646:203-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transposon mutagenesis in Clostridium difficile.
  • Genetic manipulation of Clostridium difficile is notoriously difficult, currently there is only one reliable method for generating random mutations in the organism and that is to use the conjugative transposon Tn916.
  • Tn916 enters the genome of most strains of C. difficile with no obvious target site preference.
  • In order to use the genome strain C. difficile 630 for transposon mutagenesis a erythromycin-sensitive derivative C. difficile 630Deltaerm was constructed and the Tn916 derivative, Tn916DeltaE, was shown to enter the genome at multiple sites enabling the construction of a Tn916 insertion library.
  • [MeSH-major] Clostridium difficile / genetics. Mutagenesis / genetics. Retroelements / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20597011.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / 364/E13746; United Kingdom / Medical Research Council / / G0601176
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retroelements
  •  go-up   go-down


23. |||||||||. 89%  Ben Abdelghani K, Gerard-Dran D, Morel J, Combe B: [Clostridium difficile associated reactive arthritis]. Rev Med Interne; 2010 Mar;31(3):e13-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clostridium difficile associated reactive arthritis].
  • [Transliterated title] Arthrite réactionnelle àClostridium difficile.
  • Extracolonic manifestations of Clostridium difficile infections have rarely been reported as a reactive arthritis.
  • She was admitted for fever and polyarthritis, 10 days after the onset of a C. difficile enterocolitis.
  • [MeSH-major] Arthritis, Reactive / microbiology. Clostridium difficile. Enterocolitis, Pseudomembranous / complications

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Reiter syndrome.
  • MedlinePlus Health Information. consumer health - Clostridium Difficile Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.
  • (PMID = 19457598.001).
  • [ISSN] 1768-3122
  • [Journal-full-title] La Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


24. |||||||||. 89%  Bardoň J, Vágnerová I, Kolář M: [Animal sources of Clostridium difficile]. Klin Mikrobiol Infekc Lek; 2012 Feb;18(1):9-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Animal sources of Clostridium difficile].
  • [Transliterated title] K problematice animálních zdrojů Clostridium difficile.
  • The bacterium Clostridium difficile is pathogenic for both humans and animals.
  • Identical human and animal isolates of C. difficile have been reported in several studies.
  • The article presents results from a small local study aimed at detecting C. difficile and its toxins in the District of Olomouc, Czech Republic, by 3 different methods.
  • [MeSH-major] Clostridium difficile / isolation & purification. Feces / microbiology. Sus scrofa / microbiology

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22484972.001).
  • [ISSN] 1211-264X
  • [Journal-full-title] Klinická mikrobiologie a infekc̆ní lékar̆ství
  • [ISO-abbreviation] Klin. Mikrobiol. Infekc. Lek.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


25. |||||||||. 89%  Medina-Torres CE, Weese JS, Staempfli HR: Prevalence of Clostridium difficile in horses. Vet Microbiol; 2011 Aug 26;152(1-2):212-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of Clostridium difficile in horses.
  • Fecal samples were collected to establish the apparent prevalence of Clostridium difficile shedding in Standardbred and Thoroughbred racehorses housed at 4 racetracks and 2 breeding facilities, and in horses admitted to a referral large animal clinic.
  • Forty-one (7.59%) of 540 racetrack horses, seven (5.83%) of 120 breeding farm horses, and four (4.88%) out of 82 horses admitted to the referral clinic were culture-positive for C. difficile.
  • An overall fecal culture prevalence of 7.01% for C. difficile was identified in 742 fecal samples.
  • PCR-ribotyping and toxin gene identification was performed and seventeen 17 PCR-ribotypes were identified among the 52 C. difficile isolates.
  • [MeSH-major] Bacterial Shedding. Clostridium difficile / isolation & purification. Feces / microbiology. Horses / microbiology

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 Elsevier B.V. All rights reserved.
  • (PMID = 21570780.001).
  • [ISSN] 1873-2542
  • [Journal-full-title] Veterinary microbiology
  • [ISO-abbreviation] Vet. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Bacterial Toxins
  •  go-up   go-down


26. |||||||||. 89%  Knight CL, Surawicz CM: Clostridium difficile Infection. Med Clin North Am; 2013 Jul;97(4):523-36, ix
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium difficile Infection.
  • Clostridium difficile is emerging as a common cause of infectious diarrhea.
  • Fecal microbiota transplantation is a potentially promising therapy for patients with multiple recurrences of C difficile infection.
  • [MeSH-major] Clostridium Infections. Clostridium difficile

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2013 Elsevier Inc. All rights reserved.
  • (PMID = 23809712.001).
  • [ISSN] 1557-9859
  • [Journal-full-title] The Medical clinics of North America
  • [ISO-abbreviation] Med. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antidiarrheals
  •  go-up   go-down


27. |||||||||. 88%  Monteiro MA, Ma Z, Bertolo L, Jiao Y, Arroyo L, Hodgins D, Mallozzi M, Vedantam G, Sagermann M, Sundsmo J, Chow H: Carbohydrate-based Clostridium difficile vaccines. Expert Rev Vaccines; 2013 Apr;12(4):421-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbohydrate-based Clostridium difficile vaccines.
  • Clostridium difficile is responsible for thousands of deaths each year and a vaccine would be welcomed, especially one that would disrupt bacterial maintenance, colonization and persistence in carriers and convalescent patients.
  • Structural explorations at the University of Guelph (ON, Canada) discovered that C. difficile may express three phosphorylated polysaccharides, named PSI, PSII and PSIII; this review captures our recent efforts to create vaccines based on these glycans, especially PSII, the common antigen that has precipitated immediate attention.
  • So far, it has been observed that anti-PSII antibodies can be raised in farm animals, mice and hamster models; humans and horses carry anti-PSII IgA and IgG antibodies from natural exposure to C. difficile, respectively; phosphate is an indispensable immunogenic epitope and vaccine-induced PSII antibodies recognize PSII on C. difficile outer surface.
  • [MeSH-major] Bacterial Vaccines / administration & dosage. Bacterial Vaccines / immunology. Clostridium difficile / immunology. Polysaccharides, Bacterial / immunology

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23560922.001).
  • [ISSN] 1744-8395
  • [Journal-full-title] Expert review of vaccines
  • [ISO-abbreviation] Expert Rev Vaccines
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Bacterial Vaccines; 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Polysaccharides, Bacterial; 0 / Vaccines, Conjugate
  •  go-up   go-down


28. |||||||||. 87%  Roberts AP, Mullany P: Clostridium difficile: no longer an enigmatic pathogen? Methods Mol Biol; 2010;646:3-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium difficile: no longer an enigmatic pathogen?
  • Never before has there been a more timely opportunity to investigate the molecular genetics of Clostridium difficile.
  • Over the last few years the perception of C. difficile has changed from an obscure, and often under-researched, bacterium to one of major clinical importance, at least in industrialized nations.
  • Coupled with the increased interest in this organism researchers now have a greater understanding of its genetic content and molecular epidemiology; a direct consequence of the multiple C. difficile genomes which have been, and currently are being, sequenced.
  • Concurrent with the sequencing efforts have been the development of tools to genetically manipulate the organism.
  • We are now in a position to answer fundamental questions about the biology and pathogenicity of the organism.
  • The techniques detailed in this volume should allow researchers to enter a new era of C. difficile research where it is possible, finally, to fulfil Koch's molecular postulates and determine empirically how this once enigmatic organism is able to cause disease.
  • [MeSH-major] Clostridium difficile / genetics. Clostridium difficile / pathogenicity

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • COS Scholar Universe. author profiles.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20596999.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. |||||||||. 87%  Weese JS, Wakeford T, Reid-Smith R, Rousseau J, Friendship R: Longitudinal investigation of Clostridium difficile shedding in piglets. Anaerobe; 2010 Oct;16(5):501-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal investigation of Clostridium difficile shedding in piglets.
  • A longitudinal study of Clostridium difficile colonization in piglets was performed on a conventional swine farm in Ontario, Canada.
  • Fecal samples were collected from 10 sows prior to their expected farrowing date, and then from all their piglets on days 2, 7, 30, 44 and 62 of life. C. difficile was isolated from 4/10 (40%) of sows prior to farrowing, 90/121 (74%) piglets on day 2, 66/117 (56%) on day 7, 45/113 (40%) on day 30, 23/101 (23%) on day 44 and 2/54 (3.7%) on day 62.
  • Overall, C. difficile was isolated from one or more samples from 116/121 (96%) piglets.
  • The decline in C. difficile colonization over the first 2 months of life was remarkable.
  • The variation in colonization over a relatively short period of time has important implications for the design and interpretation of studies evaluating C. difficile colonization in pigs, since relatively small differences in age may have a major confounding effect on the prevalence of colonization.
  • [MeSH-major] Bacterial Shedding. Clostridium Infections / veterinary. Clostridium difficile / pathogenicity. Swine / microbiology. Swine Diseases / epidemiology

  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20708700.001).
  • [ISSN] 1095-8274
  • [Journal-full-title] Anaerobe
  • [ISO-abbreviation] Anaerobe
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


30. |||||||||. 85%  Piacenti FJ, Leuthner KD: Antimicrobial stewardship and Clostridium difficile-associated diarrhea. J Pharm Pract; 2013 Oct;26(5):506-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antimicrobial stewardship and Clostridium difficile-associated diarrhea.
  • Antimicrobial stewardship programs are essential to health care institutions to promote the appropriate use of antibiotics not only to decrease antimicrobial resistance but to prevent the spread and infection of Clostridium difficile.
  • Clostridium difficile-associated diarrhea is increasing rapidly in the United States and is now considered a major public health problem that poses an immediate threat to the health of patients prescribed antibiotics, more so than antimicrobial resistance.
  • Clostridium difficile-associated disease is the result of collateral damage to the normal bacterial flora of the human body, which is an inevitable consequence of any antibiotic use.
  • Antimicrobial stewardship programs such as audit with feedback and antibiotic restriction are designed to help limit Clostridium difficile infections and other hospital-associated organisms by optimizing antimicrobial selection, dosing, de-escalation, and duration of therapy.
  • This article reviews the literature on how antimicrobial stewardship programs impact Clostridium difficile rates and discusses experiences in designing, implementing, monitoring, and follow-through of such programs.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Clostridium Infections / prevention & control. Diarrhea / prevention & control
  • [MeSH-minor] Clostridium difficile / isolation & purification. Cross Infection / epidemiology. Cross Infection / microbiology. Cross Infection / prevention & control. Drug Monitoring / methods. Drug Resistance, Bacterial. Humans. Practice Guidelines as Topic. United States / epidemiology

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • Genetic Alliance. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Diarrhea.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23946208.001).
  • [ISSN] 1531-1937
  • [Journal-full-title] Journal of pharmacy practice
  • [ISO-abbreviation] J Pharm Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Keywords] NOTNLM ; Clostridium difficile / antibiotic usage / antimicrobial stewardship
  •  go-up   go-down


31. ||||||||.. 84%  Headley CM: Deadly diarrhea: Clostridium difficile infection. Nephrol Nurs J; 2012 Nov-Dec;39(6):459-68; quiz 469
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deadly diarrhea: Clostridium difficile infection.
  • Diarrhea is often only a minor inconvenience, but sometimes it can be deadly--especially if it results from a Clostridium difficile infection.
  • Clostridium difficile colitis is becoming increasingly common and more virulent, and patients with kidney failure are at increased risk for development of a Clostridium disfficile infection.
  • This article provides information about Clostridium difficile infection, its incidence, diagnosis, and treatment.
  • In addition, the article discusses how to combat the transmission of Clostridium difficile infection by employing specific infection control recommendations.
  • [MeSH-major] Clostridium Infections / nursing. Clostridium difficile / isolation & purification

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • Genetic Alliance. consumer health - Diarrhea.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23469412.001).
  • [ISSN] 1526-744X
  • [Journal-full-title] Nephrology nursing journal : journal of the American Nephrology Nurses' Association
  • [ISO-abbreviation] Nephrol Nurs J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. ||||||||.. 84%  Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ: Extraintestinal Clostridium difficile infections. Clin Infect Dis; 2013 Sep;57(6):e148-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraintestinal Clostridium difficile infections.
  • BACKGROUND:  Clostridium difficile causes diarrhea that ranges from a benign, self-limiting antibiotic use-associated disease to a life-threatening pseudomembranous colitis.
  • Clostridium difficile has rarely been isolated in extraintestinal infections.
  • METHODS Extraintestinal C. difficile infections (CDIs) were searched for in an electronic database of all C. difficile-positive isolates found during a 10-year period.
  • Two patients had bacteremic infections, 4 had abdominal infections without any prior surgery, 7 had abdominal infections after surgery, 4 had perianal abscesses, 13 had wound infections, and 1 had C. difficile in a urinary catheter.
  • In most cases (85%), C. difficile was isolated together with other microbes.
  • Clostridium difficile may reach distant sites via bacteremia.
  • [MeSH-major] Bacteremia / epidemiology. Clostridium Infections / epidemiology. Clostridium difficile / isolation & purification

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23771984.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Clostridium difficile / abscess / bacteremia / postoperative complications / wound infection
  •  go-up   go-down


33. ||||||||.. 82%  Marta Piskorz M, Valentina Araya M, Piskorz EL, Sigelboim D: [Clostridium difficile and ulcerative colitis]. Acta Gastroenterol Latinoam; 2010 Dec;40(4):347-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clostridium difficile and ulcerative colitis].
  • [Transliterated title] Clostridium difficile y colitis ulcerosa.
  • Infectious colitis, including Clostridium difficile colitis, and inflammatory bowel disease are the main diagnosis that we put into consideration.
  • Because of the recurrence of the symptoms we arrived to the diagnosis of Clostridium difficile colitis complicating an ulcerative colitis.
  • Clostridium difficile colitis has particular characteristic in the context of an inflammatory bowel disease.
  • [MeSH-major] Clostridium Infections. Clostridium difficile / isolation & purification. Colitis, Ulcerative / microbiology. Diarrhea / microbiology


34. ||||||||.. 79%  Romano V, Albanese F, Dumontet S, Krovacek K, Petrini O, Pasquale V: Prevalence and genotypic characterization of Clostridium difficile from ruminants in Switzerland. Zoonoses Public Health; 2012 Dec;59(8):545-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and genotypic characterization of Clostridium difficile from ruminants in Switzerland.
  • Clostridium difficile is an emerging enteric pathogen of humans and animals with a known main reservoir in the intestinal tract of various warm-blooded animals.
  • This study was carried out to evaluate the prevalence of C. difficile in 150 rectal swab samples collected from cattle and goats in Switzerland.
  • The overall prevalence of C. difficile was 6.6%.
  • In addition, the occurrence of C. difficile in faecal samples collected from farm ground was also evaluated and C. difficile was detected in 21% (7/30) of these samples.
  • Several isolates pertained to ribotypes known to cause Clostridium difficile infections in humans.
  • [MeSH-major] Cattle Diseases / microbiology. Clostridium difficile / isolation & purification. Enterocolitis, Pseudomembranous / veterinary. Goat Diseases / microbiology. Ruminants / microbiology

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • MedlinePlus Health Information. consumer health - Clostridium Difficile Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2012 Blackwell Verlag GmbH.
  • (PMID = 22925279.001).
  • [ISSN] 1863-2378
  • [Journal-full-title] Zoonoses and public health
  • [ISO-abbreviation] Zoonoses Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


35. ||||||||.. 79%  Songer JG, Trinh HT, Killgore GE, Thompson AD, McDonald LC, Limbago BM: Clostridium difficile in retail meat products, USA, 2007. Emerg Infect Dis; 2009 May;15(5):819-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium difficile in retail meat products, USA, 2007.
  • To determine the presence of Clostridium difficile, we sampled cooked and uncooked meat products sold in Tucson, Arizona.
  • Forty-two percent contained toxigenic C. difficile strains (either ribotype 078/toxinotype V [73%] or 027/toxinotype III [NAP1 or NAP1-related; 27%]).
  • These findings indicate that food products may play a role in interspecies C. difficile transmission.
  • [MeSH-major] Cattle / microbiology. Clostridium difficile / isolation & purification. Food Contamination. Meat Products / microbiology

  • MedlinePlus Health Information. consumer health - Foodborne Illness.
  • COS Scholar Universe. author profiles.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 1982 Mar;15(3):443-6 [7076817.001]
  • [Cites] J Clin Microbiol. 1998 Aug;36(8):2240-7 [9665999.001]
  • [Cites] J Clin Microbiol. 1999 Feb;37(2):461-3 [9889244.001]
  • [Cites] Anim Health Res Rev. 2004 Dec;5(2):321-6 [15984348.001]
  • [Cites] Can Vet J. 2005 Jun;46(6):513-6 [16048011.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2433-41 [16322603.001]
  • [Cites] Emerg Infect Dis. 2008 Jul;14(7):1039-45 [18598622.001]
  • [Cites] Emerg Infect Dis. 2007 Mar;13(3):485-7 [17552108.001]
  • [Cites] Clin Infect Dis. 2007 Dec 15;45(12):1543-9 [18190314.001]
  • [Cites] Vet Microbiol. 2008 Mar 18;127(3-4):343-52 [17964088.001]
  • [Cites] Infect Control Hosp Epidemiol. 2008 Mar;29(3):197-202 [18241032.001]
  • [Cites] Emerg Infect Dis. 2008 Jun;14(6):929-31 [18507904.001]
  • [Cites] CMAJ. 2006 Sep 26;175(7):745-8 [17001054.001]
  • (PMID = 19402980.001).
  • [ISSN] 1080-6059
  • [Journal-full-title] Emerging infectious diseases
  • [ISO-abbreviation] Emerging Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Other-IDs] NLM/ PMC2687047
  •  go-up   go-down


36. ||||||||.. 79%  Enoch DA, Butler MJ, Pai S, Aliyu SH, Karas JA: Clostridium difficile in children: colonisation and disease. J Infect; 2011 Aug;63(2):105-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium difficile in children: colonisation and disease.
  • Clostridium difficile is the commonest cause of hospital acquired diarrhoea in adults and is associated with significant mortality and morbidity.
  • The clinical significance of C. difficile in children, however, is less certain.
  • In this article we discuss colonisation and infection and describe C. difficile in childhood in terms of risk factors, epidemiology and management.
  • [MeSH-major] Carrier State / epidemiology. Carrier State / microbiology. Clostridium Infections / epidemiology. Clostridium Infections / microbiology. Clostridium difficile / isolation & purification

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 21664931.001).
  • [ISSN] 1532-2742
  • [Journal-full-title] The Journal of infection
  • [ISO-abbreviation] J. Infect.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


37. ||||||||.. 78%  Limbago BM, Long CM, Thompson AD, Killgore GE, Hannett GE, Havill NL, Mickelson S, Lathrop S, Jones TF, Park MM, Harriman KH, Gould LH, McDonald LC, Angulo FJ: Clostridium difficile strains from community-associated infections. J Clin Microbiol; 2009 Sep;47(9):3004-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium difficile strains from community-associated infections.
  • Clostridium difficile isolates from presumed community-associated infections (n = 92) were characterized by toxinotyping, pulsed-field gel electrophoresis, tcdC and cdtB PCR, and antimicrobial susceptibility.
  • [MeSH-major] Clostridium difficile / classification. Clostridium difficile / isolation & purification. Community-Acquired Infections / microbiology. Enterocolitis, Pseudomembranous / microbiology

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • MedlinePlus Health Information. consumer health - Clostridium Difficile Infections.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Nov 25;341(22):1645-51 [10572152.001]
  • [Cites] J Antimicrob Chemother. 2008 Aug;62(2):388-96 [18434341.001]
  • [Cites] Clin Microbiol Infect. 2001 Aug;7(8):417-20 [11591204.001]
  • [Cites] J Clin Microbiol. 2002 Sep;40(9):3470-5 [12202595.001]
  • [Cites] J Med Microbiol. 2004 Sep;53(Pt 9):887-94 [15314196.001]
  • [Cites] J Clin Microbiol. 1979 Feb;9(2):214-9 [429542.001]
  • [Cites] J Clin Microbiol. 1992 Feb;30(2):514-6 [1537928.001]
  • [Cites] J Clin Microbiol. 1993 Jul;31(7):1870-5 [8394378.001]
  • [Cites] J Infect. 1998 May;36(3):287-8 [9661938.001]
  • [Cites] J Clin Microbiol. 1998 Aug;36(8):2240-7 [9665999.001]
  • [Cites] J Clin Microbiol. 1999 Feb;37(2):461-3 [9889244.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2433-41 [16322603.001]
  • [Cites] JAMA. 2005 Dec 21;294(23):2989-95 [16414946.001]
  • [Cites] J Infect Dis. 2006 Apr 15;193(8):1143-50 [16544255.001]
  • [Cites] J Clin Microbiol. 2008 Feb;46(2):431-7 [18039796.001]
  • [Cites] J Clin Microbiol. 2008 Mar;46(3):1157; author reply 1158 [18326836.001]
  • [Cites] FEMS Microbiol Rev. 2008 May;32(3):541-55 [18397287.001]
  • [Cites] J Med Microbiol. 2008 Jun;57(Pt 6):790-2 [18480339.001]
  • [Cites] Emerg Infect Dis. 2008 Jul;14(7):1039-45 [18598622.001]
  • [Cites] FEMS Microbiol Lett. 2000 May 15;186(2):307-12 [10802189.001]
  • (PMID = 19571021.001).
  • [ISSN] 1098-660X
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Bacterial Toxins; 0 / Repressor Proteins; 0 / TcdC protein, Clostridium difficile; EC 2.4.2.- / ADP Ribose Transferases; EC 2.4.2.31 / actin-specific ADP-ribosyltransferase, Clostridium
  • [Other-IDs] NLM/ PMC2738099
  •  go-up   go-down


38. ||||||||.. 78%  Bouillaut L, McBride SM, Sorg JA: Genetic manipulation of Clostridium difficile. Curr Protoc Microbiol; 2011 Feb;Chapter 9:Unit 9A.2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic manipulation of Clostridium difficile.
  • Clostridium difficile is a Gram-positive, spore forming, anaerobic, intestinal bacterium and is the most common cause of antibiotic-associated colitis.
  • For many years this organism was considered genetically intractable, but in the past 10 years, multiple methods have been developed or adapted for genetic manipulation of C. difficile.
  • This unit describes the molecular techniques used for genetic modification of this organism, including methods for gene disruption, complementation, plasmid introduction and integration, and cross-species conjugations.
  • [MeSH-major] Clostridium difficile / genetics. Genetic Techniques

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2011 by John Wiley & Sons, Inc.
  • [Cites] Ann Intern Med. 1966 Jul;65(1):1-8 [5936663.001]
  • [Cites] Ann Intern Med. 1974 Oct;81(4):429-33 [4412460.001]
  • [Cites] J Infect Dis. 1977 Nov;136(5):701-5 [915343.001]
  • [Cites] Gastroenterology. 1978 Nov;75(5):778-82 [700321.001]
  • [Cites] Gastroenterology. 1981 Jul;81(1):5-9 [7239125.001]
  • [Cites] J Clin Microbiol. 1987 Dec;25(12):2402-4 [2828418.001]
  • [Cites] N Engl J Med. 1989 Jan 26;320(4):204-10 [2911306.001]
  • [Cites] FEMS Microbiol Lett. 1991 Apr 15;63(2-3):191-4 [1647998.001]
  • [Cites] Gene. 1991 Jun 15;102(1):99-104 [1864514.001]
  • [Cites] Plasmid. 1992 Nov;28(3):213-24 [1334267.001]
  • [Cites] JAMA. 1993 Jan 6;269(1):71-5 [8416409.001]
  • [Cites] J Bacteriol. 1995 Feb;177(4):1112-5 [7860592.001]
  • [Cites] Nature. 1995 Jun 8;375(6531):500-3 [7777059.001]
  • [Cites] Infect Immun. 1997 Apr;65(4):1402-7 [9119480.001]
  • [Cites] Clin Infect Dis. 1998 Jan;26(1):141-5 [9455523.001]
  • [Cites] Mol Microbiol. 1998 Jan;27(1):107-20 [9466260.001]
  • [Cites] Plasmid. 1998;39(2):160-4 [9514706.001]
  • [Cites] FEMS Microbiol Lett. 1998 Nov 15;168(2):259-68 [9835037.001]
  • [Cites] Ann Surg. 1964 Sep;160:551-60 [14206857.001]
  • [Cites] Clin Microbiol Rev. 2005 Apr;18(2):247-63 [15831824.001]
  • [Cites] Lancet. 2005 Sep 24-30;366(9491):1079-84 [16182895.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2433-41 [16322603.001]
  • [Cites] Mol Microbiol. 2006 Sep;61(5):1335-51 [16925561.001]
  • [Cites] J Microbiol Methods. 2007 Sep;70(3):452-64 [17658189.001]
  • [Cites] Mol Microbiol. 2007 Oct;66(1):206-19 [17725558.001]
  • [Cites] Infect Control Hosp Epidemiol. 2007 Nov;28(11):1219-27 [17926270.001]
  • [Cites] Emerg Infect Dis. 2007 Sep;13(9):1417-9 [18252127.001]
  • [Cites] Nature. 2009 Apr 30;458(7242):1176-9 [19252482.001]
  • [Cites] J Microbiol Methods. 2009 Jul;78(1):79-85 [19445976.001]
  • [Cites] PLoS Pathog. 2009 Oct;5(10):e1000626 [19834554.001]
  • [Cites] J Bacteriol. 2009 Nov;191(22):7050-62 [19749038.001]
  • [Cites] J Bacteriol. 2009 Dec;191(23):7296-305 [19783633.001]
  • [Cites] Mol Microbiol. 2009 Nov;74(3):541-56 [19656296.001]
  • [Cites] J Biol Chem. 2009 Dec 11;284(50):34666-73 [19808679.001]
  • [Cites] J Bacteriol. 2010 Feb;192(3):657-64 [19933358.001]
  • [Cites] J Microbiol Methods. 2010 Jan;80(1):49-55 [19891996.001]
  • (PMID = 21400677.001).
  • [ISSN] 1934-8533
  • [Journal-full-title] Current protocols in microbiology
  • [ISO-abbreviation] Curr Protoc Microbiol
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK082156; United States / NIDDK NIH HHS / DK / K01 DK087763-01A1; United States / NIGMS NIH HHS / GM / K12 GM074869; United States / NIGMS NIH HHS / GM / K12 GM074869-01A1; United States / NIGMS NIH HHS / GM / K12 GM074869-02; United States / NIAID NIH HHS / AI / N01 AI030050; United States / NIAID NIH HHS / AI / N01 AI30050; United States / NIAID NIH HHS / AI / R01 AI057637; United States / NIAID NIH HHS / AI / R01 AI057637; United States / NIAID NIH HHS / AI / R01 AI057637-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS369964; NLM/ PMC3615975
  •  go-up   go-down


39. ||||||||.. 78%  Ananthakrishnan AN, Issa M, Binion DG: Clostridium difficile and inflammatory bowel disease. Gastroenterol Clin North Am; 2009 Dec;38(4):711-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium difficile and inflammatory bowel disease.
  • The past decade has seen an alarming increase in the burden of disease associated with Clostridium difficile.
  • Several studies have now demonstrated an increasing incidence of C difficile infection in patients with inflammatory bowel disease (IBD) with a more severe course of disease compared with the non-IBD population.
  • This article summarizes the available literature on the impact of C difficile infection on IBD and discusses the various diagnostic testing and treatment options available.
  • [MeSH-major] Clostridium Infections / complications. Clostridium difficile. Inflammatory Bowel Diseases / microbiology

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintIn] Med Clin North Am. 2010 Jan;94(1):135-53 [19944802.001]
  • (PMID = 19913210.001).
  • [ISSN] 1558-1942
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 90
  •  go-up   go-down


40. ||||||||.. 78%  Bakri MM, Brown DJ, Butcher JP, Sutherland AD: Clostridium difficile in ready-to-eat salads, Scotland. Emerg Infect Dis; 2009 May;15(5):817-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium difficile in ready-to-eat salads, Scotland.
  • Of 40 ready-to-eat salads, 3 (7.5%) were positive for Clostridium difficile by PCR.
  • Ready-to-eat salads may be potential sources for virulent C. difficile.
  • [MeSH-major] Clostridium difficile / isolation & purification. Food Contamination. Lettuce / microbiology. Spinacia oleracea / microbiology

  • MedlinePlus Health Information. consumer health - Foodborne Illness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hosp Infect. 2005 Sep;61(1):11-4 [16002183.001]
  • [Cites] Am J Infect Control. 2007 May;35(4):237-53 [17482995.001]
  • [Cites] Emerg Infect Dis. 2007 Mar;13(3):485-7 [17552108.001]
  • [Cites] J Med Microbiol. 2007 Jul;56(Pt 7):921-9 [17577057.001]
  • [Cites] J Food Prot. 2007 Aug;70(8):1966-74 [17803159.001]
  • [Cites] Infect Immun. 1999 Oct;67(10):5124-32 [10496886.001]
  • [Cites] J Clin Microbiol. 2004 Mar;42(3):1035-41 [15004050.001]
  • [Cites] J Infect Dis. 1992 Sep;166(3):561-7 [1323621.001]
  • [Cites] J Med Microbiol. 1996 Aug;45(2):133-7 [8683549.001]
  • [Cites] J Clin Microbiol. 1999 Feb;37(2):461-3 [9889244.001]
  • [Cites] J Food Prot. 2003 Mar;66(3):403-9 [12636292.001]
  • (PMID = 19402979.001).
  • [ISSN] 1080-6059
  • [Journal-full-title] Emerging infectious diseases
  • [ISO-abbreviation] Emerging Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bacterial Proteins; 0 / Bacterial Toxins; 0 / Enterotoxins; 0 / tcdA protein, Clostridium difficile; 0 / toxB protein, Clostridium difficile
  • [Other-IDs] NLM/ PMC2687046
  •  go-up   go-down


41. ||||||||.. 78%  Rogers MA, Greene MT, Saint S, Chenoweth CE, Malani PN, Trivedi I, Aronoff DM: Higher rates of Clostridium difficile infection among smokers. PLoS One; 2012;7(7):e42091
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher rates of Clostridium difficile infection among smokers.
  • We investigated whether smoking affected the probability of developing Clostridium difficile infection (CDI).
  • CONCLUSIONS: Smoking is associated with developing a Clostridium difficile infection.
  • [MeSH-major] Clostridium difficile / pathogenicity. Enterocolitis, Pseudomembranous / epidemiology. Smoking

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • MedlinePlus Health Information. consumer health - Clostridium Difficile Infections.
  • MedlinePlus Health Information. consumer health - Smoking.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Epidemiol Community Health. 1991 Dec;45(4):270-2 [1795144.001]
  • [Cites] BMC Microbiol. 2012;12:48 [22452857.001]
  • [Cites] J Clin Microbiol. 1995 Oct;33(10):2757-8 [8567919.001]
  • [Cites] J Med Microbiol. 1996 Aug;45(2):133-7 [8683549.001]
  • [Cites] Lancet. 1998 Feb 28;351(9103):633-6 [9500319.001]
  • [Cites] Arch Intern Med. 2004 Nov 8;164(20):2206-16 [15534156.001]
  • [Cites] J Gen Intern Med. 2005 Aug;20(8):697-702 [16050877.001]
  • [Cites] Emerg Infect Dis. 2006 Mar;12(3):409-15 [16704777.001]
  • [Cites] Mayo Clin Proc. 2006 Nov;81(11):1462-71 [17120402.001]
  • [Cites] Emerg Infect Dis. 2007 Mar;13(3):485-7 [17552108.001]
  • [Cites] Epidemiol Infect. 2007 Aug;135(6):1010-3 [17156501.001]
  • [Cites] Curr Pharm Des. 2009;15(13):1403-14 [19442165.001]
  • [Cites] Environ Health Perspect. 2010 Mar;118(3):351-6 [20064769.001]
  • [Cites] Ann N Y Acad Sci. 2010 Dec;1213:62-9 [21175676.001]
  • [Cites] PLoS One. 2010;5(12):e15216 [21188149.001]
  • [Cites] J Antimicrob Chemother. 2011 Sep;66(9):2159-67 [21719472.001]
  • [Cites] Gut Microbes. 2011 May-Jun;2(3):145-58 [21804357.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2012 Mar 9;61(9):157-62 [22398844.001]
  • [Cites] BMJ. 1993 Nov 27;307(6916):1381-4 [8274889.001]
  • (PMID = 22848714.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / 5U19AI090871-02; United States / NIA NIH HHS / AG / U01AG009740
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3407081
  •  go-up   go-down


42. ||||||||.. 78%  He X, Wang J, Steele J, Sun X, Nie W, Tzipori S, Feng H: An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins. J Microbiol Methods; 2009 Jul;78(1):97-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins.
  • We describe a novel ultrasensitive cell-based immunocytotoxicity assay for detecting Clostridium difficile toxin A and B.
  • Using this assay, we were able to detect the presence of C. difficile toxins in the fecal and serum specimens of experimentally infected piglets.
  • [MeSH-major] Bacterial Toxins / isolation & purification. Biological Assay / methods. Clostridium difficile / chemistry. Cytotoxicity Tests, Immunologic / methods. Cytotoxins / isolation & purification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Intensive Care Med. 2000 Apr;26(4):416-21 [10872133.001]
  • [Cites] Infect Immun. 2009 Jun;77(6):2294-303 [19307220.001]
  • [Cites] J Clin Microbiol. 2003 Feb;41(2):531-4 [12574241.001]
  • [Cites] J Immunol Methods. 2004 Sep;292(1-2):195-205 [15350524.001]
  • [Cites] J Infect Dis. 1979 Nov;140(5):765-70 [231071.001]
  • [Cites] Infect Immun. 1987 Nov;55(11):2789-96 [3666963.001]
  • [Cites] N Engl J Med. 1989 Jan 26;320(4):204-10 [2911306.001]
  • [Cites] Int Immunol. 1997 Feb;9(2):239-48 [9040006.001]
  • [Cites] Annu Rev Med. 1998;49:375-90 [9509270.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14176-81 [16966605.001]
  • [Cites] Ann Intern Med. 2006 Nov 21;145(10):758-64 [17116920.001]
  • [Cites] Clin Infect Dis. 2007 Nov 1;45(9):1152-60 [17918076.001]
  • [Cites] N Engl J Med. 2008 Oct 30;359(18):1932-40 [18971494.001]
  • [Cites] Lancet Infect Dis. 2008 Dec;8(12):777-84 [18977696.001]
  • [Cites] BMC Microbiol. 2008;8:192 [18990232.001]
  • [Cites] N Engl J Med. 2002 Jan 31;346(5):334-9 [11821511.001]
  • (PMID = 19393695.001).
  • [ISSN] 1872-8359
  • [Journal-full-title] Journal of microbiological methods
  • [ISO-abbreviation] J. Microbiol. Methods
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K01 DK076549; United States / NIDDK NIH HHS / DK / K01 DK076549-01A1; United States / NIDDK NIH HHS / DK / K01DK076549; United States / NIAID NIH HHS / AI / N01AI30050
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Bacterial Toxins; 0 / Cytotoxins
  • [Other-IDs] NLM/ NIHMS126645; NLM/ PMC2740367
  •  go-up   go-down


43. ||||||||.. 78%  Ananthakrishnan AN, Issa M, Binion DG: Clostridium difficile and inflammatory bowel disease. Med Clin North Am; 2010 Jan;94(1):135-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clostridium difficile and inflammatory bowel disease.
  • The past decade has seen an alarming increase in the burden of disease associated with Clostridium difficile.
  • Several studies have now demonstrated an increasing incidence of C difficile infection in patients with inflammatory bowel disease (IBD) with a more severe course of disease compared with the non-IBD population.
  • This article summarizes the available literature on the impact of C difficile infection on IBD and discusses the various diagnostic testing and treatment options available.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintOf] Gastroenterol Clin North Am. 2009 Dec;38(4):711-28 [19913210.001]
  • (PMID = 19944802.001).
  • [ISSN] 1557-9859
  • [Journal-full-title] The Medical clinics of North America
  • [ISO-abbreviation] Med. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. ||||||||.. 78%  Bandelj P, Trilar T, Racnik J, Zadravec M, Pirš T, Avbersek J, Micunovic J, Ocepek M, Vengust M: Zero prevalence of Clostridium difficile in wild passerine birds in Europe. FEMS Microbiol Lett; 2011 Aug;321(2):183-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zero prevalence of Clostridium difficile in wild passerine birds in Europe.
  • Clostridium difficile is an important bacterial pathogen of humans and a variety of animal species, where it can cause significant medical problems.
  • The major public health concern is the possibility of inapparent animal reservoirs of C. difficile and shedding of bacteria to noninfected individuals or populations, as well as being a source of food contamination.
  • Therefore, the purpose of this study was to investigate whether migrating passerine birds can be a source of spread of C. difficile along their migration routes.
  • Selective enrichment was used for detection of C. difficile.
  • Clostridium difficile was not isolated from any of the samples, which indicates that migrating passerine birds are unlikely to serve as a reservoir and a carrier of C. difficile.
  • [MeSH-major] Carrier State / microbiology. Clostridium Infections / veterinary. Clostridium difficile / isolation & purification. Passeriformes / microbiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. No claim to original Slovenian government works.
  • (PMID = 21658108.001).
  • [ISSN] 1574-6968
  • [Journal-full-title] FEMS microbiology letters
  • [ISO-abbreviation] FEMS Microbiol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


45. ||||||||.. 77%  Metcalf D, Reid-Smith RJ, Avery BP, Weese JS: Prevalence of Clostridium difficile in retail pork. Can Vet J; 2010 Aug;51(8):873-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of Clostridium difficile in retail pork.
  • Clostridium difficile was isolated from 1.8% (7/393) of retail pork samples obtained from 4 Canadian provinces.
  • Although the implications for food safety practices remain elusive, the frequency of toxigenic isolates and isolates indistinguishable from known human pathogenic strains suggests contaminated pork may be a source of C. difficile in humans.
  • [MeSH-major] Clostridium difficile / isolation & purification. Consumer Product Safety. Food Contamination / analysis. Meat / microbiology

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • MedlinePlus Health Information. consumer health - Foodborne Illness.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEMS Microbiol Lett. 2000 May 15;186(2):307-12 [10802189.001]
  • [Cites] J Clin Microbiol. 2008 Sep;46(9):2999-3004 [18650360.001]
  • [Cites] J Infect Dis. 2004 May 1;189(9):1585-9 [15116293.001]
  • [Cites] CMAJ. 2004 Aug 31;171(5):466-72 [15337727.001]
  • [Cites] J Med Microbiol. 1996 Aug;45(2):133-7 [8683549.001]
  • [Cites] J Infect. 1998 May;36(3):287-8 [9661938.001]
  • [Cites] J Clin Microbiol. 1998 Aug;36(8):2240-7 [9665999.001]
  • [Cites] FEMS Microbiol Lett. 1999 Jun 15;175(2):261-6 [10386377.001]
  • [Cites] J Clin Microbiol. 2004 Dec;42(12):5710-4 [15583303.001]
  • [Cites] J Med Microbiol. 2005 Feb;54(Pt 2):163-6 [15673511.001]
  • [Cites] Lancet. 2005 Sep 24-30;366(9491):1079-84 [16182895.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2433-41 [16322603.001]
  • [Cites] J Clin Microbiol. 2006 Jun;44(6):2147-52 [16757612.001]
  • [Cites] J Clin Microbiol. 2007 Jan;45(1):215-21 [17035492.001]
  • [Cites] Vet Microbiol. 2007 Feb 25;120(1-2):179-83 [17112686.001]
  • [Cites] Emerg Infect Dis. 2006 Nov;12(11):1730-6 [17283624.001]
  • [Cites] Clin Microbiol Infect. 2007 May;13(5):457-9 [17331126.001]
  • [Cites] J Clin Microbiol. 2007 Jun;45(6):1963-4 [17428945.001]
  • [Cites] Emerg Infect Dis. 2007 Mar;13(3):485-7 [17552108.001]
  • [Cites] J Clin Microbiol. 2008 Mar;46(3):1157; author reply 1158 [18326836.001]
  • [Cites] Vet Microbiol. 2008 May 25;129(1-2):209-14 [18164560.001]
  • [Cites] J Med Microbiol. 2008 Jun;57(Pt 6):790-2 [18480339.001]
  • [Cites] Int J Food Microbiol. 2008 Jun 10;124(3):268-70 [18448182.001]
  • [Cites] Euro Surveill. 2008 Jul 31;13(31). pii: 18942 [18761903.001]
  • [Cites] J Clin Microbiol. 2002 Sep;40(9):3470-5 [12202595.001]
  • (PMID = 21037888.001).
  • [ISSN] 0008-5286
  • [Journal-full-title] The Canadian veterinary journal. La revue vétérinaire canadienne
  • [ISO-abbreviation] Can. Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2905007
  •  go-up   go-down


46. ||||||||.. 77%  Chmelarová E, Skapová T: [Practical experience with the detection Clostridium difficile]. Klin Mikrobiol Infekc Lek; 2010 Jun;16(3):86-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Practical experience with the detection Clostridium difficile].
  • [Transliterated title] Praktické zkusenosti s diagnostikou Clostridium difficile.
  • Clostridium difficile is an important pathogen causing nosocomial diarrhoea and colitis which, in severe cases, may result in pseudomembranous colitis and eventually death.
  • The main pathogenicity factors for C. difficile are toxins referred to as A and B.
  • The diagnosis of diseases caused by C. difficile is based on detection of the toxins, together with culture and determination of susceptibility of C. difficile strains to antibiotics.
  • The article reports results of tests of kits for detecting C. difficile toxins VIDAS(c) C. difficile Toxin A & B (bioMérieux) and Toxin A Test (Oxoid) in 170 stool samples.
  • Also reported are results of the determination of MICs of vancomycin and metronidazole in 302 strains of C. difficile cultured in the bacteriology laboratory of the Institute of Public Health in Ostrava in 2008-2009.
  • [MeSH-major] Clostridium difficile / isolation & purification
  • [MeSH-minor] Clostridium Infections / microbiology. Enterocolitis, Pseudomembranous / microbiology. Humans. Microbial Sensitivity Tests

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • ExactAntigen/Labome. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20640985.001).
  • [ISSN] 1211-264X
  • [Journal-full-title] Klinická mikrobiologie a infekc̆ní lékar̆ství
  • [ISO-abbreviation] Klin. Mikrobiol. Infekc. Lek.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


47. ||||||||.. 77%  Monaghan T, Boswell T, Mahida YR: Recent advances in Clostridium difficile-associated disease. Postgrad Med J; 2009 Mar;85(1001):152-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in Clostridium difficile-associated disease.
  • The main purpose of this article is to review recent developments in the management of acute and recurrent Clostridium difficile-associated disease, with consideration of existing and new antibiotic and non-antibiotic agents for treatment.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Clostridium difficile. Enterocolitis, Pseudomembranous / drug therapy


48. ||||||||.. 77%  Bauer MP, van Dissel JT: Alternative strategies for Clostridium difficile infection. Int J Antimicrob Agents; 2009 Mar;33 Suppl 1:S51-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternative strategies for Clostridium difficile infection.
  • Although antibiotics are generally effective in achieving symptomatic recovery from Clostridium difficile infection, the disease frequently relapses, partly because antibiotics not only kill C. difficile, but also disrupt colonisation resistance of the gut microflora.
  • Non-antibiotic strategies for the prevention and treatment of the infection include probiotics, deliberate colonisation by non-toxigenic C. difficile strains, toxin-binding agents, active immunisation, passive immunotherapy with intravenous immunoglobulin, monoclonal antibodies or bovine anti-C. difficile whey concentrate, and faecal transplantation.
  • [MeSH-major] Antibiosis. Clostridium difficile / growth & development. Enterocolitis, Pseudomembranous / prevention & control. Enterocolitis, Pseudomembranous / therapy

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • MedlinePlus Health Information. consumer health - Clostridium Difficile Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19303571.001).
  • [ISSN] 1872-7913
  • [Journal-full-title] International journal of antimicrobial agents
  • [ISO-abbreviation] Int. J. Antimicrob. Agents
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 33
  •  go-up   go-down


49. ||||||||.. 77%  Diggs NG, Surawicz CM: Evolving concepts in Clostridium difficile colitis. Curr Gastroenterol Rep; 2009 Oct;11(5):400-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolving concepts in Clostridium difficile colitis.
  • Clostridium difficile infection (CDI) is the most important cause of nosocomial diarrhea.
  • In patients with inflammatory bowel disease, the risk of C. difficile infection is even greater, with higher rates of hospitalization, bowel surgery, and mortality.
  • [MeSH-major] Clostridium Infections / diagnosis. Cross Infection / diagnosis. Irritable Bowel Syndrome / diagnosis

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19765368.001).
  • [ISSN] 1534-312X
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


50. ||||||||.. 77%  Madan R, Jr WA: Immune responses to Clostridium difficile infection. Trends Mol Med; 2012 Nov;18(11):658-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune responses to Clostridium difficile infection.
  • Clostridium difficile is the causal agent of antibiotic-associated diarrhea and is a leading cause of hospital-acquired infections in the US. C. difficile has been known to cause severe diarrhea and colitis for more than 30 years, but the emergence of a newer, hypervirulent strain of C. difficile (BI/NAP1) has further compounded the problem, and recently both the number of cases and mortality associated with C. difficile-associated diarrhea have been increasing.
  • A better understanding of the host inflammation and immune mechanisms that modulate the course of disease and control host susceptibility to C. difficile could lead to novel (host-targeted) strategies for combating the challenges posed by this deadly infection.
  • This review summarizes our current knowledge of the host inflammatory response during C. difficile infection.
  • [MeSH-major] Adaptive Immunity. Clostridium difficile / immunology. Enterocolitis, Pseudomembranous / immunology. Immunity, Innate

  • Genetic Alliance. consumer health - Clostridium Difficile.
  • MedlinePlus Health Information. consumer health - Clostridium Difficile Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2012 Elsevier Ltd. All rights reserved.
  • [Cites] J Immunol. 1999 Nov 15;163(10):5183-91 [10553038.001]
  • [Cites] N Engl J Med. 2000 Feb 10;342(6):390-7 [10666429.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):1147-56 [10772660.001]
  • [Cites] Am J Gastroenterol. 2000 Nov;95(11):3137-41 [11095331.001]
  • [Cites] Lancet. 2001 Jan 20;357(9251):189-93 [11213096.001]
  • [Cites] Mol Microbiol. 2001 Jun;40(5):1187-99 [11401722.001]
  • [Cites] Infect Immun. 2001 Dec;69(12):7937-40 [11705981.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):725-33 [11875005.001]
  • [Cites] Mol Gen Genet. 1992 May;233(1-2):260-8 [1603068.001]
  • [Cites] Eur J Pediatr. 1993 Apr;152(4):319-22 [8482281.001]
  • [Cites] J Clin Invest. 1994 Mar;93(3):1257-65 [7907603.001]
  • [Cites] Gastroenterology. 1994 Sep;107(3):657-65 [7915699.001]
  • [Cites] J Clin Invest. 1994 Nov;94(5):1919-26 [7962537.001]
  • [Cites] Gut. 1996 Mar;38(3):337-47 [8675084.001]
  • [Cites] Gastroenterology. 1997 Jun;112(6):1887-94 [9178681.001]
  • [Cites] Gastroenterology. 1998 May;114(5):956-64 [9558284.001]
  • [Cites] J Immunol. 1998 Jun 15;160(12):6039-45 [9637520.001]
  • [Cites] Infect Immun. 1998 Nov;66(11):5462-9 [9784558.001]
  • [Cites] Ann Intern Med. 1998 Dec 15;129(12):1012-9 [9867755.001]
  • [Cites] Infect Immun. 1999 Feb;67(2):527-38 [9916055.001]
  • [Cites] Am J Physiol. 1999 Feb;276(2 Pt 1):G485-90 [9950823.001]
  • [Cites] J Clin Invest. 1999 Mar;103(6):843-9 [10079105.001]
  • [Cites] J Med Microbiol. 2005 Feb;54(Pt 2):193-6 [15673516.001]
  • [Cites] Infect Control Hosp Epidemiol. 2005 Mar;26(3):273-80 [15796280.001]
  • [Cites] Clin Microbiol Rev. 2005 Apr;18(2):247-63 [15831824.001]
  • [Cites] Clin Infect Dis. 2005 Jun 1;40(11):1591-7 [15889355.001]
  • [Cites] Lancet. 2005 Sep 24-30;366(9491):1079-84 [16182895.001]
  • [Cites] CMAJ. 2005 Oct 25;173(9):1037-42 [16179431.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2442-9 [16322602.001]
  • [Cites] N Engl J Med. 2005 Dec 8;353(23):2433-41 [16322603.001]
  • [Cites] J Infect Dis. 2006 Apr 15;193(8):1143-50 [16544255.001]
  • [Cites] Emerg Infect Dis. 2006 Mar;12(3):409-15 [16704777.001]
  • [Cites] Infect Immun. 2006 Nov;74(11):6339-47 [16966409.001]
  • [Cites] Int J Infect Dis. 2007 Jan;11(1):5-10 [16857405.001]
  • [Cites] Infect Immun. 2007 Aug;75(8):3868-76 [17517880.001]
  • [Cites] Am J Gastroenterol. 2007 Dec;102(12):2781-8 [17900327.001]
  • [Cites] Clin Infect Dis. 2008 Jan 15;46 Suppl 1:S19-31 [18177218.001]
  • [Cites] J Med Microbiol. 2008 Jun;57(Pt 6):717-24 [18480328.001]
  • [Cites] Gut. 2009 Jan;58(1):34-40 [18824554.001]
  • [Cites] Microb Pathog. 2009 Jun;46(6):298-305 [19324080.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Aug;7(8):868-873.e2 [19465153.001]
  • [Cites] PLoS Pathog. 2009 Oct;5(10):e1000626 [19834554.001]
  • [Cites] N Engl J Med. 2010 Jan 21;362(3):197-205 [20089970.001]
  • [Cites] PLoS One. 2010;5(1):e8740 [20090901.001]
  • [Cites] Vaccine. 2010 Jan 22;28(4):965-9 [19941990.001]
  • [Cites] Arch Intern Med. 2010 May 10;170(9):772-8 [20458084.001]
  • [Cites] Clin Microbiol Rev. 2010 Jul;23(3):529-49 [20610822.001]
  • [Cites] Gastroenterology. 2010 Aug;139(2):542-52, 552.e1-3 [20398664.001]
  • [Cites] J Bacteriol. 2010 Oct;192(19):4983-90 [20675492.001]
  • [Cites] Nature. 2010 Oct 7;467(7316):711-3 [20844489.001]
  • [Cites] Clin Infect Dis. 2010 Dec 15;51(12):1406-10 [21058913.001]
  • [Cites] J Immunol. 2011 Jan 1;186(1):423-31 [21131421.001]
  • [Cites] N Engl J Med. 2011 Feb 3;364(5):422-31 [21288078.001]
  • [Cites] Future Microbiol. 2011 Feb;6(2):121-3 [21366410.001]
  • [Cites] J Clin Microbiol. 2011 Mar;49(3):858-65 [21177896.001]
  • [Cites] Int J Antimicrob Agents. 2009 Mar;33 Suppl 1:S24-8 [19303565.001]
  • [Cites] Nature. 2009 Apr 30;458(7242):1176-9 [19252482.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1048-57 [11910356.001]
  • [Cites] Microbiol Immunol. 2002;46(5):333-42 [12139393.001]
  • [Cites] Infect Immun. 2002 Oct;70(10):5770-8 [12228307.001]
  • [Cites] Infect Control Hosp Epidemiol. 2002 Nov;23(11):653-9 [12452292.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):683-91 [12612907.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):3018-25 [14978106.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8503-8 [15159534.001]
  • [Cites] N Engl J Med. 1978 Mar 9;298(10):531-4 [625309.001]
  • [Cites] Gastroenterology. 1978 Nov;75(5):778-82 [700321.001]
  • [Cites] Pharmacol Ther. 1981;13(3):441-52 [7280010.001]
  • [Cites] Infect Immun. 1981 Dec;34(3):1036-43 [7333662.001]
  • [Cites] J Infect Dis. 1983 Jul;148(1):93-100 [6886489.001]
  • [Cites] Infect Immun. 1985 Feb;47(2):349-52 [3917975.001]
  • [Cites] Infect Immun. 1987 Jul;55(7):1541-6 [3596798.001]
  • [Cites] J Infect Dis. 1990 Sep;162(3):678-84 [2387993.001]
  • [Cites] Infect Immun. 1991 Jun;59(6):2215-8 [2037383.001]
  • [Cites] Infect Control Hosp Epidemiol. 1991 Jun;12(6):345-8 [2071877.001]
  • [Cites] Infect Immun. 2011 Apr;79(4):1498-503 [21245274.001]
  • [Cites] Infect Control Hosp Epidemiol. 2011 Mar;32(3):220-8 [21460506.001]
  • [Cites] Infect Control Hosp Epidemiol. 2011 Apr;32(4):387-90 [21460491.001]
  • [Cites] J Immunol. 2011 Apr 15;186(8):4872-80 [21411735.001]
  • [Cites] PLoS Pathog. 2011 Jun;7(6):e1002076 [21738466.001]
  • [Cites] J Med Microbiol. 2011 Aug;60(Pt 8):1162-7 [21349985.001]
  • [Cites] J Med Microbiol. 2011 Aug;60(Pt 8):1070-9 [21415200.001]
  • [Cites] BMC Infect Dis. 2011;11:194 [21762504.001]
  • [Cites] Gut Microbes. 2011 May-Jun;2(3):145-58 [21804357.001]
  • [Cites] FEMS Immunol Med Microbiol. 2011 Oct;63(1):73-81 [21707776.001]
  • [Cites] Clin Infect Dis. 2011 Nov;53(10):994-1002 [22002980.001]
  • [Cites] PLoS Pathog. 2011 Oct;7(10):e1002317 [22022270.001]
  • [Cites] N Engl J Med. 2011 Nov 3;365(18):1693-703 [22047560.001]
  • [Cites] Curr Opin Gastroenterol. 2012 Jan;28(1):1-9 [22134217.001]
  • [Cites] Infect Immun. 2012 Jan;80(1):62-73 [22006564.001]
  • [Cites] Am J Gastroenterol. 2012 Jan;107(1):89-95 [22108454.001]
  • [Cites] Trends Microbiol. 2012 Jan;20(1):21-9 [22154163.001]
  • (PMID = 23084763.001).
  • [ISSN] 1471-499X
  • [Journal-full-title] Trends in molecular medicine
  • [ISO-abbreviation] Trends Mol Med
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / U54 AI057168
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacterial Toxins; 0 / Inflammation Mediators; 0 / Virulence Factors
  • [Other-IDs] NLM/ NIHMS415474; NLM/ PMC3500589
  •  go-up   go-down


top


2. Definitions


3. Related RMF webpages


terms of use | advertising programs | contact us
© 2014 RecentMedicalFindings


Connect with the


RMF


audience;




Post your ad here!